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Summary 
Attention-deficit/hyperactivity disorder (ADHD) is a genetically complex childhood onset 
neurodevelopmental disorder which is highly persistent into adulthood. Several chromo-
somal regions associated with this disorder were identified previously in genome-wide 
linkage scans, association (GWA) and copy number variation (CNV) studies. 
In this work the results of case-control and family-based association studies using a can-
didate gene approach are presented. For this purpose, possible candidate genes for ADHD 
have been finemapped using mass array-based SNP genotyping. The genes KCNIP4, 
CDH13 and DIRAS2 have been found to be associated with ADHD and, in addition, with 
cluster B and cluster C personality disorders (PD) which are known to be related to ADHD. 
Most of the associations found in this work would not withstand correction for multiple 
testing. However, a replication in several independent populations has been achieved and 
in conjunction with previous evidence from linkage, GWA and CNV studies, it is assumed 
that there are true associations between those genes and ADHD. 
Further investigation of DIRAS2 by quantitative real-time PCR (qPCR) revealed expression 
in the hippocampus, cerebral cortex and cerebellum of the human brain and a significant 
increase in Diras2 expression in the mouse brain during early development. In situ hybrid-
izations on murine brain slices confirmed the results gained by qPCR in the human brain. 
Moreover, Diras2 is expressed in the basolateral amygdala, structures of the olfactory 
system and several other brain regions which have been implicated in the psychopatholo-
gy of ADHD. 
In conclusion, the results of this work provide further support to the existence of a strong 
genetic component in the pathophysiology of ADHD and related disorders. KCNIP4, 
CDH13 and DIRAS2 are promising candidates and need to be further examined to get 
more knowledge about the neurobiological basis of this common disease. This knowledge 
is essential for understanding the molecular mechanisms underlying the emergence of 
this disorder and for the development of new treatment strategies. 
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Zusammenfassung 
Bei Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom (ADHS) handelt es sich um eine ge-
netisch komplexe neuronale Entwicklungsstörung, die im Kindesalter einsetzt und eine 
hohe Persistenz ins Erwachsenenalter aufweist. Mehrere chromosomale Regionen zeigten 
eine Assoziation mit dieser Erkrankung in genomweiten Kopplungsanalysen, Assoziations- 
(GWA) und Copie Number Variation (CNV) Studien. 
In dieser Arbeit werden die Ergebnisse von Fall-Kontroll- und Familien-basierten Assozia-
tionsstudien, basierend auf der Annahme bestimmter Kandidatengene, vorgestellt. Die 
möglichen Kandidatengene wurden mit Hilfe eines massenspektrometrischen Verfahrens 
für SNP Genotypisierungen untersucht. Für die Gene KCNIP4, CDH13 und DIRAS2 konnte 
eine Assoziation mit ADHS und zudem mit Persönlichkeitsstörungen gefunden werden. 
Die meisten der in dieser Arbeit berichteten Assoziationen würden einer Korrektur für 
multiples Testen nicht standhalten. Dennoch kann von einer tatsächlichen Assoziation 
dieser Gene mit ADHS ausgegangen werden da eine Replikation in verschiedenen unab-
hängigen Stichproben stattgefunden hat und zudem vorangegangene Kopplungsanalysen, 
GWA und CNV Studien auf eine Assoziation hindeuten. 
Die weitere Untersuchung des DIRAS2 Gens mit Hilfe von quantitativer real-time PCR 
(qPCR) ergab eine Expression des Gens im Hippocampus, dem zerebralen Kortex und dem 
Kleinhirn des Menschen. Zudem wurde ein signifikanter Anstieg der Diras2 Expression im 
murinen Gehirn während der frühen Entwicklungsstadien beobachtet. In situ Hybridisie-
rungen auf Maushirnschnitten bestätigten die Ergebnisse der qPCR im menschlichen Ge-
hirn. Außerdem wird Diras2 in der basolateralen Amygdala, in Komponenten des olfakto-
rischen Systems und in mehreren anderen Hirnarealen, die vermutlich an der Pathologie 
von ADHS beteiligt sind, exprimiert. 
Zusammenfassend untermauern die Ergebnisse dieser Arbeit die Tatsache dass eine star-
ke genetische Komponente an der Entstehung von ADHS beteiligt ist. KCNIP4, CDH13 und 
DIRAS2 sind vielversprechende Kandidatengene und sollten weiter untersucht werden um 
nähere Einblicke in die Neurobiologie dieser häufigen Erkrankung zu erhalten. Das 
dadurch erlangte Wissen ist notwendig um die molekularen Mechanismen die ADHS zu-
grunde liegen zu verstehen und um neue Behandlungsstrategien entwickeln zu können. 
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1. Introduction 
1.1. Attention-deficit/hyperactivity disorder 
Phenotype and diagnosis 
Attention-deficit/hyperactivity disorder (ADHD) is an early onset childhood neurodevel-
opmental disorder. With a prevalence of 3% - 5% it is one of the most common psychiat-
ric disorders in children (Renner 2008a). 
 
According to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV), ADHD diagnosis is based on two symptomatic dimensions: inattention and hy-
peractivity/impulsivity. For the diagnosis of the inattentive or the hyperactive/impulsive 
subtype of ADHD, at least six of nine criteria for one category have to be met. If six or 
more symptoms of both dimensions are present, the combined subtype of ADHD is diag-
nosed. ADHD is observed in males more often than in females. Phenotypic gender differ-
ences are also observed. Girls suffering from ADHD are more likely affected by the inat-
tentive subtype which is less salient. Therefore, it is possible that girls with ADHD might 
stay undiagnosed as compared to boys (Biederman 2002). Although ADHD was first per-
ceived as a childhood disease, it is now well accepted to be highly persistent into adult-
hood. 
 
A common clinical feature of ADHD is its comorbidity with other psychiatric diseases. In 
children, the occurrence of oppositional defiant disorder (ODD), conduct disorders (CD), 
unipolar and bipolar mood disorders, anxiety disorders, learning disorders, autism and 
other pervasive developmental disorders together with ADHD is often observed 
(Biederman, 2005). In adults with ADHD, comorbidities with anxiety disorders, mood dis-
orders, personality disorders (PD) and alcohol/substance abuse disorders were reported 
(Jacob 2007). In addition, it has been reported that patients with ADHD in childhood are 
more likely to be diagnosed with PD in late adolescence (Miller 2008). According to the 
DSM – IV, PDs are subdivided in three clusters. Cluster A (odd or eccentric cluster) com-
prises paranoid and schizoid disorders, cluster B (dramatic, emotional or erratic cluster) 
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includes antisocial, borderline and narcissistic personality disorders, and cluster C (anx-
ious or fearful cluster) consisting of avoidant, dependent and obsessive-compulsive per-
sonality disorders.  
 
A cumulative appearance of ADHD within families can be observed and several studies 
verified the familiarity of ADHD. In adoption studies a higher likelihood for hyperactivity 
in biological relatives of children with ADHD as compared to adopted relatives was found. 
Twin studies revealed a heritability of ADHD of almost 80% (Faraone 2005). Those find-
ings indicate that there exists a strong genetic component in the origin of ADHD. 
 
Molecular genetics of ADHD 
To identify chromosomal regions which harbor genes for ADHD, whole genome linkage 
studies can be conducted. Those studies are based on families with multiple affected sib-
lings and examine if any chromosomal regions are shared among family members more 
often than expected by chance. For this purpose, genetic markers like single nucleotide 
polymorphisms (SNPs) which are spread throughout the human genome are investigated. 
Several of such studies identifying possible susceptibility loci for ADHD have been pub-
lished in the last years. For example Romanos et al. reported linkage at the chromosomal 
regions 2q35, 5q13.1, 6q22-23, 7q21.11, 9q22, 14q12 and 16q24.1 across eight investi-
gated families (Romanos 2008a). Zhou et al. performed a meta-analysis of seven inde-
pendent genome-wide linkage scans including the study described above. A genome-wide 
significant linkage on chromosome 16 and additional suggestive or nominal evidence of 
linkage for nine other loci was found (Figure 1.1) (Zhou K. , 2008). 
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Figure 1.1:  Meta-analysis of seven independent genome-wide linkage scans by Zhou et al. 
Weighted (red) and unweighted (blue) −log10(PSR). The thresholds of nominal 
(P = 0.05) suggestive (P = 0.0083) and genome-wide significant linkage 
(P = 0.000417 after Bonferroni correction) are shown (Zhou K. , 2008) 
 
To search for susceptibility genes for ADHD in a hypothesis-free approach, genome-wide 
association studies (GWAS) can be used. For those studies hundreds of thousands of 
markers across the human genome are tested for an association with the disease by 
comparing patients versus control individuals. To overcome the issue of multiple testing, 
very large sample sizes are needed for GWAS. One of the first GWAS on ADHD was con-
ducted by the International Multicenter ADHD Genetics (IMAGE) project. In their first 
study (IMAGE I) in 909 affected family trios consisting of the parents and one affected 
child, none of the 438 784 tested SNPs achieved genome-wide significance (Neale 2008). 
The data gained in this study were also tested for an association with quantitative traits 
generated from ADHD symptoms. Two SNPs showed significance within a specific pheno-
type. Those markers are found in the intronic regions of the CDH13 and the GFOD1 gene. 
Additional 17 genes had association p values < 0.01 (Lasky-Su 2008). A second GWAS of 
the IMAGE consortium (IMAGE II) testing more than 1 million SNPs for an association with 
ADHD in 896 cases and 2455 controls failed to identify genome-wide significant associa-
tions as well. However, the most significant results implicated some interesting candidate 
genes. Notably, the CDH13 gene was amongst those (Neale 2010a). Meta-analysis of the 
IMAGE I and IMAGE II data and datasets of two additional GWAS on ADHD also revealed 
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no genome-wide significant findings, suggesting that the effect sizes of common variants 
must be very small (Neale 2010b). A pooling-based GWAS of adult ADHD (aADHD) found a 
large number of top-ranked SNPs in the regions of genes which are expressed in the brain 
including CTNNA2, ASTN2 and CDH13 (Lesch 2008). 
 
In candidate gene studies selected genes are tested for an association with a disease. Se-
lection of potential candidate genes is usually based on findings of linkage studies or 
GWAS, animal studies or theoretical considerations implicating a role of the gene in the 
pathomechanism of ADHD. A case-control design comparing the allele frequencies of pa-
tients and control subjects is possible for these studies as well as a family-based design in 
which the transmission rates of alleles from parents to ADHD children are determined. 
The genes investigated with this approach so far are for the most part components of the 
dopaminergic system. But also genes involved in the serotonergic and other neurotrans-
mitter systems as well as genes playing a role in transmitter release have been considered 
as candidate genes for ADHD. The most frequently studied genes of the dopaminergic 
system are the dopamine D4 receptor gene (DRD4), the dopamine D5 receptor gene 
(DRD5) and the gene coding for the dopamine transporter (DAT, SLC6A3). The 7-repeat 
allele of a tandem repeat polymorphism in exon 3 of DRD4 was found in several studies to 
be associated with ADHD. In the DRD5 gene the 148bp allele of a dinucleotide polymor-
phism was associated with ADHD in several family-based studies and meta-analyses 
(Faraone 2005). Significant association between a tandem repeat polymorphism in the 3´ 
untranslated region (UTR) of the DAT gene and ADHD was found in several meta-analyses 
and pooled analyses (Stergiakouli and Thapar, 2010). A study of 776 ADHD cases found 
several SNPs located in the 3´ UTR and in the 5´flanking region of DAT1 to be associated 
with the disease (Brookes 2006). Also genes involved in other neurotransmitter systems 
than the dopaminergic one have been reported to be associated with ADHD. To these 
belong the serotonin 1B receptor gene (HTR1B), the serotonin transporter gene (5-HTT) 
and the gene coding for the α-4 subunit of the nicotinic acetylcholine receptor (CHRNA4) 
(Faraone 2005). 
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The contribution of environmental factors in ADHD 
As ADHD is, like other psychiatric disorders a genetically complex disease, it is also influ-
enced by environmental factors. It is documented that maternal smoking and alcohol ex-
posure during pregnancy and low birth weight are risk factors for ADHD. Pregnancy and 
delivery complications are thought to predispose for ADHD as well. Psychosocial adversi-
ties like chronic family conflict, decreased family cohesion and exposure to parental psy-
chopathology are found in ADHD families more often than in control families (Biederman 
1995). Such psychosocial factors are considered as nonspecific triggers of an underlying 
predisposition for ADHD (Biederman, 2005). 
 
Neurobiology of ADHD 
A dysbalance in the dopaminergic and noradrenergic systems is often assumed to be a 
cause for the main symptoms of ADHD. Results of neurobiological, neuroimaging and 
neuropsychological studies suggest that deficits in frontal lobe function and the connec-
tions between the frontal lobe and subcortical regions are of vital importance for this dis-
order. In structural imaging studies changes in brain anatomy like smaller frontal cortex 
volumes as well as smaller volumes in subcortical structures and the cerebellum have 
been found in patients suffering from ADHD (Castellanos 2002) (Sowell 2003). The sub-
cortical structures caudate nucleus, putamen and globus pallidus were reported as al-
tered in ADHD patients by imaging studies. In addition, larger hippocampal volumes have 
been reported in children and adults suffering from ADHD compared to controls (Plessen 
2006). The same study found the basolateral complex of the amygdala to be smaller in 
children with ADHD than in controls. Most of the fronto-subcortical systems implicated in 
ADHD are catecholaminergic. Catecholamines are involved in the mechanisms of action of 
medications for ADHD treatment. Substances like methylphenidate inhibit the dopamine 
transporter and therefore stop the reuptake of dopamine and norepinephrine from the 
synaptic cleft. Many models for the effects of ADHD medication are discussed. One is 
suggesting for example that, via the effect on the dopaminergic and noradrenergic path-
ways, the inhibition of subcortical structures by frontal cortical activity is increased 
(Biederman, 2005). 
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1.2.  Kv channel-interacting protein 4 (KCNIP4) 
A single marker situated in the intron of the KCNIP4 gene which is located on Chr. 4p15.31 
in humans was among the top 25 results of a transmission disequilibrium testing (TDT)-
based GWAS on childhood ADHD (cADHD) conducted by the IMAGE project (Neale 2008). 
The same marker also showed nominal association with ADHD in a GWAS of quantitative 
traits for ADHD (Lasky-Su 2008). In addition, several SNPs within the KCNIP4 locus 
emerged in a GWAS on aADHD (Lesch 2008) and in a GWAS on PD conducted in our 
group. The location of the markers found to be associated with ADHD and PD is shown in 
Figure 1.2. Remarkably, the SNPs that were found to be associated with PD are clustered 
at the 5´region of the gene while those that emerged in the two GWAS on ADHD are 
mainly located in the 3´region and central regions of KCNIP4. Additionally, the KCNIP4 
locus was among the top 25 results of GWAS on schizophrenia (Sullivan 2008), emphasiz-
ing its possible role in psychiatric disorders. 
 
 
Figure 1.2: Location of SNPs at the KCNIP4 locus associated with ADHD or PD 
SNP IDs are shown in different colors according to the GWAS in which 
they emerged. Most SNPs associated with PD are clustered at the 
3´region while the ADHD associated ones are located more upstream. 
Black = GWAS on cADHD (Neale 2008); Red = GWAS on aADHD (Lesch 
2008); Blue = GWAS on PD 
 
The Kv channel-interacting protein 4 (KCNIP4, KChIP4) which is encoded by the KCNIP4 
gene was first described as a binding protein of presenilin (PS) and as a novel KCNIP pro-
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tein by Morohashi et al. in 2002 (Morohashi 2002). KCNIP proteins are known as calcium 
binding proteins that are interaction partners of the voltage-gated potassium channel 
subunit Kv4 family. This family of subunits is believed to be responsible for the A type 
potassium current in neurons which is defined as a low-threshold, rapidly activating cur-
rent that inactivates very fast. This current regulates the firing rate of neurons and the 
sensitivity to synaptic inputs at the soma and the dendrites. KCNIP4 has been reported to 
be co-localized with the potassium channel subunit Kv4.2 in the apical and basal dendrites 
of hippocampal and neocortical pyramidal cells in the rat brain (Rhodes 2004). In the 
mouse brain it was present in the mitral cell layer of the olfactory bulb, the piriform cor-
tex, in layers II – IV of the cerebral cortex, in the hippocampus, the thalamus and the 
Purkinje cells of the cerebellum (Xiong 2004) (Pruunsild and Timmusk, 2005).  
 
While the C terminal domains of the four KCNIP proteins (KCNIP1 – 4) are conserved core 
regions containing EF-hand Ca2+ binding motifs, the N termini of those proteins are highly 
variable and share no homology with other calcium binding protein domains. There are 
different isoforms of KCNIP4 which differ in their N termini due to alternative splicing or 
alternative transcription start sites. So far, six predominant transcripts of the human 
KCNIP4 gene have been described (Pruunsild and Timmusk, 2005). One isoform of KCNIP4 
(KCNIP4a) which contains a K-channel inactivation suppressor (KIS) domain has been 
found to slow down the closing of Kv4.3 channels and therefore to retard the inactivation 
of the A type potassium current (Holmqvist 2002). The same splice variant KCNIP4a was 
found to be expressed in a cell type specific manner in the rat brain, leading to a slower 
potassium current inactivation in cells in the globus pallidus and the basal forebrain com-
pared to striatal and hippocampal neurons which do not express this isoform 
(Baranauskas, 2004). 
 
In addition to its function in the regulation of potassium currents through its interaction 
with Kv4 subunits, KCNIP4 has been initially reported to interact with presenilin which is 
known to be involved in early onset Alzheimer´s disease. A possible implication of this 
interaction has been found by a group that examined the orphan nuclear receptor Nurr1. 
This receptor plays an essential role in the development of dopaminergic neurons in the 
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midbrain that regulate motor control. According to their results, Kitagawa et al. postulate 
a model (see Figure 1.3) in which Nurr1 is bound to co-repressor molecules as long as 
there is no signal of the Wnt family of secreted glycoproteins. After Wnt mediated β-
catenin transport to the nucleus, Nurr1 associated proteins are switched from co-
repressors to co-activators. Nurr1 and β-catenin induce KCNIP4 which associates with a 
PS complex and promotes β-catenin degradation in a negative feedback loop (Kitagawa 
2007). As the Wnt/β-catenin pathway plays an important role in the development of the 
nervous system, it can be assumed that KCNIP4 is also involved in developmental pro-
cesses in the brain. 
 
 
Figure 1.3: Model of the role of KNIP4 interaction with Presenilin (Kitagawa 2007) 
Molecules acting as co-repressors are bound to Nurr1 as long as there is no Wnt signal. After 
Wnt mediated β-catenin accumulation in the nucleus, co-repressors are switched to co-
activators. Nurr1 and β-catenin induce KCNIP4 which associates with a PS complex and pro-
motes β-catenin degradation in a negative feedback loop 
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1.3. Cadherin 13 (CDH13) 
The gene coding for Cadherin 13 (CDH13; also called T-Cad for Truncated Cadherin or H-
Cad for Heart Cadherin) emerged in several GWAS on ADHD and other psychiatric disor-
ders. The CDH13 gene is located on chromosome 16, in a chromosomal region (16q24) 
that was described as a linkage locus in a genome-wide linkage analysis of ADHD 
(Romanos 2008a). Moreover, the gene lies within the only significant linkage region found 
in a meta-analysis of genome-wide linkage scans of ADHD (Zhou K. , 2008). An intronic 
SNP in the CDH13 gene was one of the top 30 single marker association findings in a 
GWAS on adult ADHD (Lesch 2008). In addition, a marker situated upstream of the CDH13 
gene was found to be over-transmitted in a family-based GWAS of ADHD (Neale 2008). 
Another intronic SNP within this gene was the most significant association finding in a 
GWAS of quantitative traits in ADHD conducted with the data gained in the family-based 
study from Neale et al. 2008 (Lasky-Su 2008). In a case control-based GWAS of childhood 
ADHD, the CDH13 gene again was one of the top 100 candidates (Neale 2010a). Finally, a 
candidate gene approach in a meta-analysis of GWAS of ADHD revealed no genome-wide 
significant results, but 26 SNPs within the CDH13 gene were among the top 50 results 
(Neale 2010b). Beyond its association with ADHD, the CDH13 gene has been found to be 
associated with a wide range of other psychiatric disorders such as alcoholism (Treutlein 
2009), methamphetamine dependence (Uhl 2008) and schizophrenia (Sullivan 2008). 
 
Besides its strong expression in the cardiovascular system, CDH13 is highly expressed in 
the brain. In humans, lower expression levels have been found in the developing brain 
than in the adult brain. In human adult brains, CDH13 expression is reported in the cere-
bral cortex, the medulla oblongata, the thalamus and the midbrain (Takeuchi 2000). 
Cadherins are known to mediate calcium-dependent intercellular adhesion. Cadherin13 is 
an atypical cadherin since it shares the 5 extracellular cadherin repeat domain (EC1-5) 
structure but lacks a transmembrane domain and has no cytoplasmic domain. Instead it 
contains a hydrophobic sequence that serves as a signal for glycosylphosphatidylinositol 
(GPI) anchor attachment. Via this GPI anchor, Cadherin13 is attached to the plasma 
membrane of the cell. Cadherin13 has been found to act as a negative guidance signal to 
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motor axons (Fredette 1996). In endothelial cells, Cadherin13 promotes deadhesion and 
polarization of cells via the RhoA/ROCK and the Rac pathway (Philippova 2005). Further-
more, signaling of Cadherin13 through PI3K/Akt/GSK3β pathways, in which integrin linked 
kinase (ILK) is an essential mediator, has been shown in endothelial cells (Joshi 2007). The 
membrane proteins Grp78 and Intergrin β3 are thought to play an important role in Cad-
herin13 dependent endothelial cell survival mediated via the Akt pathway (Philippova 
2008). It has also been shown that Cadherin13 can mediate cell proliferation and migra-
tion initiated by low density lipoprotein (LDL) via the phospholipase C (PLC) which is acti-
vating the ERK1/2 pathway (Kipmen-Korgun 2005). The different signaling mechanisms 
via which Cadherin13 acts are illustrated in Figure 1.4 (borrowed from Philippova et al.).  
 
 
Figure 1.4: Signaling mechanisms activated by Cadherin13 (Philippova 2009) 
(A) Cadherin13 promotes proliferation and survival of endothelial cells via activation of the 
PI3K/Akt/mTOR survival pathway. To exert these functions GPI-anchored Cadherin13 must 
engage molecular transmembrane adaptors like Grp78 (pink), integrin-β3 (purple) and/or in-
tracellular adaptors e.g. integrin linked kinase (ILK) (yellow) which facilitate inward signal 
transduction pathway activation. (B) Homophilic Cadherin13 ligation in endothelial cells in-
duces cell deadhesion and polarization via RhoA/ROCK- and Rac-dependent signaling mecha-
nisms. (C) Cadherin13 is able to bind the low-density lipoprotein (LDL). This interaction leads 
to activation of phospholipase C (PLC), inositol trisphosphate (IP3) formation, intracellular 
Ca
2+
 mobilization, activation of the tyrosine kinases ERK1/2 followed by mitogenic responses. 
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1.4.  Distinct subgroup of the Ras family member 2 (DIRAS2) 
Two SNPs on chromosome 9q2.22 were among the 500 top ranking markers in a GWAS 
on aADHD (Lesch 2008). Additionally, this locus emerged in two linkage studies. One was 
conducted in individuals recruited in the same environs as those in the aADHD GWAS 
(Romanos 2008a), the other one was performed in the UK (Asherson 2008). The chromo-
somal region comprises the Distinct subgroup of the Ras family member 2 (DIRAS2) gene 
which is known to be uniquely expressed in the brain with high expression levels in the 
cerebral cortex, occipital pole, frontal and temporal lobe and cerebellum (Kontani 2002).  
 
The human Ras superfamily of small guanosine triphosphatases (GTPases) consists of 
more than 150 members and is divided in five subfamilies: Ras, Rho, Rab, Ran and Arf. 
Small GTPases share a common biochemical mechanism and act as molecular switches 
that regulate many cell functions like proliferation and differentiation. A common feature 
of small GTPases is their high affinity binding of guanosine diphosphate (GDP) and guano-
sine triphosphate (GTP), with the GTP-bound molecule representing the active state. 
GDP/GTP cycling is controlled by two classes of regulatory proteins. Activation of small 
GTPases is promoted by guanine nucleotide exchange factors, whereas GTPase-activating 
proteins accelerate the intrinsic GTPase activity to promote formation of the inactive 
GDP-bound form (Wennerberg 2005).  
 
Although related in sequence, Di-ras proteins (Di-ras1 and Di-ras2) differ in their biochem-
ical and functional properties from other Ras family members. Like most Ras kinases they 
have a highly conserved GTP-binding domain, an effector domain and a membrane local-
izing motif at the carboxyl terminus. However, there are amino acid substitutions present 
at positions that are critical for GTP hydrolysis. This biochemical property fits to the find-
ing that Di-ras proteins are found mainly in GTP-bound form in living cells. Kontani et al. 
found that Di-ras2 neither activates the mitogen activated protein kinase (MAPK) path-
way, nor induces Akt activation which is a downstream target of phosphoinositide 3 ki-
nase (PI3K).  
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As Di-ras2 has significant homology to Aplasia Ras homolog member I (ARHI, NOEY2, Di-
ras3) which has been identified as a tumor suppressor, both proteins may have similar 
roles in cell function (Kontani 2002). In breast and ovarian cancer a loss of ARHI expres-
sion due to promoter methylation is observed. There is evidence that ARHI inhibits cell 
growth through several pathways including the MAPK, the PI3K and the STAT3 pathways. 
Reexpression of ARHI in human ovarian cancer cell lines and ARHI overexpression in xen-
ograft tumors leads to an inactivation of the mammalian target of rapamycin (mTOR) (Lu 
2008) (Zhao 2010). mTOR regulates protein synthesis through the inactivation of the re-
pressor of mRNA translation, eukaryotic initiation factor 4E-binding protein (4E-BP1), and 
through the activation of S6 kinase (S6K1). One of the upstream effectors of mTOR is Akt 
which, as mentioned above, is part of the PI3K signaling cascade (Hay and Sonenberg, 
2004). The mTOR pathway is rapidly activated by ketamine and results in rapid and sus-
tained elevation of synapse associated proteins and spine number in the prefrontal cortex 
(PFC) of rats. This might represent a mechanism for the rapid antidepressant actions of 
ketamine (Li 2010). Therefore, the mTOR pathway plays an important role not only in the 
origin of psychiatric diseases but also in their treatment. Taken together, these facts indi-
cate a possible role of Di-ras2 in the control of cell growth.  
 
A study investigating the distinct transcriptomes of serotonergic neurons found Diras2 
expression increased 13 fold in serotonergic neurons isolated from the caudal hindbrain 
of mouse embryos, pointing to a role in the regulation of the caudal serotonergic system 
(Wylie 2010). A GWAS on cognitive performance of the aging brain revealed DIRAS2 to be 
associated with performance in the Boston naming test indicating a role of DIRAS2 in 
cognitive processes (Seshadri 2007). However, it is still not known via which pathways Di-
ras2 acts and which function it accomplishes. 
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2. Material and Methods 
2.1. Material 
2.1.1. Human samples 
A total of 1659 patients suffering from aADHD were available for genotyping. All patients 
were evaluated by experienced psychiatrists and diagnosed with persistent ADHD accord-
ing to DSM-IV (Diagnostic and Statistical Manual for Mental Disorders) criteria along a 
semi-structured interview. Consensus eligibility criteria for this study across all study sites 
were a diagnosis of ADHD according to the diagnostic criteria of DSM-IV, onset before the 
age of 7 years by retrospective diagnosis (which was confirmed by a family member, 
wherever possible), life-long persistence and current diagnosis. Additionally, scales on 
disease severity as well as co-morbid conditions have been included. 624 patients were 
recruited in Germany, 285 in The Netherlands, 497 in Norway and 253 in Spain. Individu-
als were aged 18 – 65 years. Patients suffering from addictive disorders, bipolar disorders, 
schizophrenia or mental retardation were excluded. The healthy control group consisted 
of 2478 individuals altogether, 630 of which were collected in the Lower Franconia area 
of Germany, 467 in Munich in Germany, 508 in The Netherlands, 562 in Norway and 311 
in Spain (Jacob 2007) (Franke 2010). 
 
The family-based childhood ADHD sample from Würzburg comprises of 171 families, of 
which 113 are trios, 43 are quartets and 15 are multi sibling families. 142 family trios 
were recruited in Homburg, Germany. All of the children in both samples were affected 
by the combined subtype of ADHD according to DSM-IV criteria. Exclusion criteria were an 
intelligence quotient < 80, autism, Tourette syndrome and severe primary psychiatric dis-
orders (Renner 2008b) (Neale 2010a). 
 
In addition to the adult and childhood ADHD samples, genotyping of a PD sample and of a 
bipolar disorder sample was conducted for some candidate genes. The PD sample con-
sisted of 708 patients from Germany diagnosed with personality disorder according to 
criteria of DSM-IV and assigned to cluster B and cluster C using the SCID-II. The bipolar 
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sample consisted of 214 unrelated bipolar patients from the German Lower Franconia 
area for whom an ICD-10 diagnosis was established by means of an extensive, semi-
structured interview carried out by two experienced psychiatrists at the Department of 
Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg. A further 166 
unrelated bipolar patients were ascertained according to ICD-10 diagnostic criteria for 
research (DCR) by means of a semi-structured interview at the Center for Psychiatric Re-
search, Århus University Hospital, Risskov, Denmark, giving a total number of 380 patients 
suffering from bipolar disorder (Jacob 2005) (Scholz 2010). 
2.1.2. Animals 
All animals were housed in a colony room under controlled temperature and humidity 
conditions, with lights on between 6:00 a.m. and 6:00 p.m., with food and water freely 
available. All animal protocols have been reviewed and approved of the review boards of 
the University of Würzburg and of the Government of Unterfranken (Bavaria, Germany), 
and were in accordance with international guiding principles of the care and use of ani-
mals. 
For in situ hybridization, qPCR and western blotting experiments adult C57BL/6J wild-type 
mice were decapitated in isoflurane anesthesia. Brains were dissected and immediately 
frozen in dry ice-cooled isopentane (AppliChem, Darmstadt, Germany) and tissue was 
stored at -80°C. 
For hippocampal primary cell culture the embryos (C57BL/6J background, wild-type) of a 
2 – 3 month old pregnant mouse were obtained at embryonic day 18 (E18).The mother 
animals were sacrificed by cervical dislocation or exposure to isoflurane (Forene®, Abbott, 
Illinois, USA). 
2.1.3. Cell lines 
The human cell lines A172 (glioblastoma), U373 (astrocytoma), SK-N-SH (neuroblastoma) 
and HEK293 (immortalized human embryonic kidney cells) have been used for western 
blotting analyses. 
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2.2. Association studies 
2.2.1. SNP selection 
The SNP IDs (rs numbers) of SNPs located within the sequence of a potential candidate 
gene plus the 5´ and 3´ flanking sequences were downloaded from the HapMap genome 
browser. In the case of genes with very long sequences, the selection was narrowed down 
to the SNPs located in the exons and their flanking intronic sequences. Tagging SNP selec-
tion was performed using the tagger algorithm of the Haploview software for pair-wise 
tagging with a r2 threshold > 0.8 and a minor allele frequency > 5% (Barrett 2005). 
 
2.2.2. Mass array-based SNP genotyping 
SNP genotyping was conducted using the MassArray® system (Sequenom, San Diego, CA). 
For the so called iPLEX™ assay, genomic DNA isolated from blood conduced as template 
for a multiplex PCR. Up to 30 different DNA fragments, each harboring one SNP were am-
plified in this reaction using 100 nM primers (Metabion, Martinsried, Germany), 0.5 U 
HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany), 500 µM dNTPs (Promega, Madi-
son, WI, USA), 1.25x Hotstar PCR buffer (Qiagen) and 1.625 mM MgCl2 (Qiagen) in a total 
volume of 5 µl. PCRs were performed using a Biometra thermocycler (Biometra, Göttin-
gen, Germany) The reaction conditions were as follows: 
 
Step Purpose Temperature Time Repeats 
1 Denaturation 94°C 15 min 1 
2 Denaturation 94°C 20 sec 
44 3 Annealing 56°C 30 sec 
4 Amplification 72°C 1 min 
5 Amplification 72°C 3 min 1 
6 Cooling 10°C until end  
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PCR products underwent treatment with shrimp alkaline phosphatase (SAP) at 37°C for 20 
min to dephosphorylate unincorporated dNTPs. The next step was a single base extension 
of primers that bind to the amplified DNA immediately adjacent to the SNPs of interest. 
This reaction was done using mass modified ddNTPs and 0.625 µM of low mass primers 
and 1.25 µM of high mass primers under the following conditions: 
 
Step Purpose Temperature Time Repeats 
1 Denaturation 94°C 30 sec 1 
2 Denaturation 94°C 5 sec 
40 3 Annealing 52°C 5 sec 
4 Extension 80°C 5 sec 
5 Extension 72°C 3 min 1 
 
After desalting the samples with 6 mg SpectroCLEAN™ resin (Sequenom), 40 nl of each 
reaction was spotted onto a SpectroCHIP™ (Sequenom) using the Sequenom MassAR-
RAY™ Nanodispenser. Mass spectrometric analysis was carried out on a Bruker Autoflex 
time-of-flight mass spectrometer (MALDI-TOF; Bruker Daltonics, Billerica, MA, USA). 
 
2.2.3. Statistical analyses 
Mass spectra were all checked by eye for quality control before the statistical evaluation. 
Statistical analyses of genotyping data was done by Thuy Trang Nguyen at the institute for 
medical biometry and epidemiology of the Philipps University in Marburg, Germany. Only 
SNPs passing quality check, which was defined by MAF >0.01, call rate >80% and p value 
of χ² test for Hardy-Weinberg equilibrium >0.01 in controls or parents, were analyzed. 
Inconsistent genotypes in the family sample were revealed and removed by means of 
PedCheck (O'Connell and Weeks, 1998). Generalized linear models (GLM) implemented in 
the R function glm() were carried out to test for an association between SNP genotype as 
independent variable and a trait of interest as dependent variable (binary: ADHD, bipolar, 
cluster B and C PD; quantitative: NEO-PI R and TPQ). Binomial logit link or Gaussian identi-
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ty link was used for binary or quantitative traits, respectively. In addition, Fisher’s exact 
test was performed in order to assure the asymptotic test results of glm(). Family-based 
association analysis was carried out using pedigree disequilibrium test (Martin 2000) to 
assess whether an allele is more frequently transmitted to affected offspring.  
 
The omnibus test implemented in famhap (10,000 simulations; (Becker and Knapp, 2004)) 
was used to test the global hypothesis that association with ADHD may be contributed to 
by at least one of the estimated haplotypes. The LD blocks were defined by pairwise 
D’>0.65 assessed using Haploview. For haplotype-specific association testing Unphased 
(Dudbridge, 2008) was used. 
 
For the meta analysis, Woolf's test for heterogeneity, obtained with the R function me-
ta.MH(), was performed. A joint analysis assessing the common odds ratio (OR) was done 
by means of GLM described above, adjusted for fixed country effect. 
Unless otherwise specified, p values are two-sided p values unadjusted for multiple test-
ing. The significance level was set to 0.05. The Bonferroni method was used to calculate p 
values adjusted for testing multiple SNPs and haplotypes for association with ADHD. 
Power calculations were performed under a two-sided nominal significance level of 0.05 
using QUANTO Version 1.0 (http://hydra.usc.edu/gxe). 
 
2.3.  Expression studies 
2.3.1. Quantitative real-time analyses 
RNA isolation and cDNA synthesis 
RNA isolation from mouse brain tissue was conducted by Dr. Claudia Kriegebaum using 
the trizol procedure (Invitrogen™, LIFE TECHNOLOGIES, USA) followed by purification and 
removal of potential remaining genomic DNA with the RNeasy kit (QIAGEN, Hilden, Ger-
many) in combination with DNase I treatment. RNA concentration and quality were de-
termined using the automated electrophoresis system Experion™ (Biorad, Munich, Ger-
many) as described in the appertaining manual. In addition, human total RNA of different 
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brain regions (cerebral cortex, hippocampus, putamen, caudate nucleus, cerebellum, 
pons and medulla oblongata) was obtained from BD Biosciences (Erembodegem, Bel-
gium). This RNA was pooled from 10-35 male and female Caucasians (16-70 years). 
500 ng of total RNA were reversely transcribed into complementary DNA in a 20 µl reac-
tion volume using the iScript™ cDNA synthesis kit (Biorad, Munich, Germany). After the 
reverse transcription reaction the cDNA was diluted 1:5 with DEPC treated water. 
 
Quantitative real-time polymerase chain reaction (qPCR) 
For quantitative real-time PCR the IQ™ SYBR® Green supermix (Biorad, Munich, Germany) 
and Quantitec primer assays (QIAGEN, Hilden, Germany) or self-designed primers were 
used. The oligonucleotides used in this work are listed in Table 2.1 and Table 2.2. The vol-
ume of each reaction was 10 µl containing 1x IQ™ SYBR® Green supermix, 1x Quantitec 
primers or 500 nM of each oligonucleotide primer and 1µl of the diluted cDNA. PCR and 
fluorescence measurements were run in the CFX384™ Real-Time PCR detection system 
(Biorad, Munich, Germany). The reaction conditions were as followed: 
 
Step Purpose Temperature Time Repeats 
1 Denaturation 95°C 15 min 1 
2 Denaturation 95°C 30 sec 
40 
3 
Annealing 
Amplification 
Fluorescence meas-
urement 
60°C 45 sec 
4 Denaturation 95°C 1 min 1 
5 Melting curve 
55°C – 95°C  
(0.5°C steps) 
10 sec per step  
6 Cooling 15°C until end  
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Species Gene 
GenBank  
accession No 
Primer 
Amplicon 
length 
Mus 
musculus 
Beta-actin NM_007393  Mm_Actb_2_SG 149 bp 
Glyceraldehyde-3-
phosphate dehydro-
genase  
NM_01001303  Mm_Gapdh_3_SG 100 bp 
Ubiquitin C  NM_019639  Mm_Ubc_1_SG 75 bp 
18s ribosomal RNA X00686  Mm_Rn18s_2_SG 149 bp 
Beta-2 microglobulin NM_009735 Mm_B2m_2_SG 143 bp 
Ribosomal protein, 
large, P0 
NM_007475 Mm_Rplp0_1_SG 125 bp 
Latrophilin 3 NM_198702 Mm_Lphn3_2_SG 104 bp 
Homo 
sapiens 
Beta-actin NM_001101 Hs_ACTB_2_SG 104 bp 
Glyceraldehyde-3-
phosphate dehydro-
genase 
NM_002046 Hs_GAPDH_2_SG 119 bp 
18s ribosomal RNA X03205 Hs_RRN18S_1_SG 149 bp 
Aminolevulinate delta 
synthase 1 
NM_000688 Hs_ALAS1_1_SG 113 bp 
Peptidylprolyl isomer-
ase A 
NM_001008741 Hs_PPIA_4_SG 121 bp 
Table 2.1:  Quantitec primer assays used for quantitative real-time PCR 
 
Species Gene 
GenBank ac-
cession No 
Primer Sequence 5´- 3´ 
Mus 
musculus 
Diras2  NM_001024474 Mm_Diras2_Ex1_for GAGCTGCGCCTGGAGACCTG 
Diras2 NM_001024474 Mm_Diras2_Ex2_rev CCGCCACCCGGTAGTCGTTG 
Homo 
sapiens 
Diras2 NM_017594 Diras2_Ex1_for CGAGTGGAGCTCTGAAGAAG 
Diras2 NM_017594 Diras2_Ex2_rev GGCATGTTGCTGGAGAGC 
Table 2.2: Self-designed primer pairs used for quantitative real-time PCR 
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Determination of expression levels and statistical analyses 
PCR efficiencies were determined based on raw data using the software tool LinReg. This 
tool calculates the PCR efficiency for each individual sample from the slope of the regres-
sion line fitted to a subset of baseline-corrected data points in the log-linear phase 
(Ramakers 2003). Baseline correction of threshold cycle (Ct) values was performed by the 
CFX Manager™ software (Biorad, Munich, Germany). Relative quantities (Q values) were 
obtained by applying the following formula: 
 
Q value = PCR efficiency [Minimum (Ct values) – Ct value] 
 
To normalize the Q values of the investigated target genes, normalization factors were 
calculated based on the relative quantities of several reference genes. Firstly, the gene 
expression stability values (M) for those reference genes were calculated. Then the Q 
values of the two to three genes showing the most stable expression were used for nor-
malization factor determination using the GeNorm algorithm. (Vandesompele 2002) To 
get the normalized expression levels, the Q values of the target genes were divided by the 
normalization factor for each sample. Statistical evaluation of expression data was done 
running a Kruskal-Wallis test over all groups testing for a group effect. If this test showed 
significant group differences (p value< 0.05), a Mann-Whitney test for detecting differ-
ences between two groups was performed. The significance threshold was Bonferroni 
corrected for multiple testing. 
 
2.3.2. RNA in situ hybridization 
cRNA probe synthesis 
A Diras2 specific cDNA fragment was synthesized by reverse transcription of total RNA 
isolated from mouse brains followed by a PCR using the following primers: 
Sonde_Diras2_Mm F (forward): 5´- GAGAAGCTCAAGGGCAAGTG -3´ 
Sonde_Diras2_Mm R (reverse): 5´- CATCTGCCTGCCTACTCCTC -3´ 
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The 445bp PCR product was cloned into the pCRII® dual promotor vector using the TOPO® 
TA cloning® kit dual promotor according to the manufacturer´s instructions (Invitrogen™, 
LIFE TECHNOLOGIES, USA). 
The vector construct served as template for the generation of digoxigenin (DIG) labeled 
cRNA probes by in vitro transcription. Therefore, the vector was linearized by a restriction 
digest using either XhoI (sense) or BamHI (antisense) and cleaned up using the QIAquick 
PCR purification kit (Qiagen, Inc. Valencia, CA, USA). cRNA probe synthesis and DIG label-
ing was performed using SP6 RNA polymerase for the sense and T7 RNA polymerase for 
the antisense probe generation and the DIG RNA labeling mix (Roche, Mannheim, Ger-
many). For riboprobe clean-up RNeasy Mini columns (Qiagen, Inc. Valencia, CA, USA) 
were used according to the manufacturer´s directions. To the eluted probes the same 
volume of 100% formamide was added. 
 
In situ hybridization (ISH) 
In situ hybridization was performed as described by Palop et. al. (Palop 2011). 10 µm cry-
ostat sections of native mouse brains were fixed for 10 min with 4% PFA in 1x PBS. After 
washing with PBS sections were digested with 1 µg/ml proteinase K in 50 mM Tris-HCl (pH 
8.0)/5 mM EDTA buffer for 30 min and fixed again in 4% PFA for 5 min. Once washed with 
PBS, sections were incubated in acetylation solution containing 1.355% triethanolamine, 
0.175% HCl and 0.25% acetic anhydride for 10 min followed by three washes with PBS. 
For pre hybridization slides were covered with hybridization buffer (50% formamide, 5× 
salt sodium citrate (SSC) buffer, pH 7.0, 5× Denhardt’s solution, 0.25 mg/ml salmon sperm 
DNA) and incubated for 4 h at room temperature in a humidified chamber. DIG labeled 
riboprobes and hybridization buffer were heated at 70°C for 3 min. The riboprobes were 
added to the hybridization buffer in a final concentration of 500 – 1000 ng/ml. 100 µl of 
this hybridization solution was added on each slide, covered with parafilm and incubated 
at 72°C overnight. To remove unbound probes the sections were washed with 5x SSC for 
10 min and three times with 0.2x SSC for 30 min at 72°C followed by a 5 min wash with 
0.2x SSC and a 5 min wash with 1x TBS at room temperature. To block nonspecific bind-
ing, the slides were transferred to a humidified chamber and 500 µl of 1x TBS with 10% 
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heat inactivated sheep serum (HISS) were added on each slide for 1 h at room tempera-
ture. Blocking solution was replaced with 500 µl of a 1:5,000 dilution of anti-digoxigenin 
antibody-AP (Roche, Mannheim, Germany) in TBS with 3% HISS and incubated at 4°C 
overnight. After several washes with TBS and equilibration with NTMT buffer (0.1 M Tris–
HCl, pH 9.5, 0.1 M NaCl, 50 mM MgCl2) color development was conducted using a 1:50 
dilution of NBT/BCIP stock solution (Roche, Mannheim, Germany) in NTMT buffer over-
night in the dark. Color reaction was stopped by washing the slides in PBS/EDTA (0.1 M 
PBS, 1 µM EDTA pH 8.0), fixed for 10 min with 4%PFA in PBS and washed in PBS. Finally, 
sections were rinsed with distilled water to remove salts and coverslipped using Aquatex® 
(Merck, Darmstadt, Germany). 
 
2.3.3. Western blot analyses 
Protein lysates 
Cells and tissues were lysed using Nonidet-P40 (NP40) buffer consisting of 150 mM sodi-
um chloride, 1 % NP40 and 50 mM Tris (pH 8.0). For the preparation of cell lysates 166 µl 
ice cold NP40 buffer containing proteinase inhibitor cocktail (Roche, Mannheim, Germa-
ny) was added per 25 cm2 cell culture flask. Adherent cells were removed from the flask 
using a plastic cell scraper and the cell suspension was transferred to a microfuge tube 
and sonicated for 15 sec. 
 
For tissue lysates 100 µl NP40 buffer containing proteinase inhibitor cocktail (Roche, 
Mannheim, Germany) was added per 20 mg of brain tissue. The tissue was separated us-
ing the Tissue LyserII (Qiagen, Inc. Valencia, CA, USA) for 30 sec followed by sonication for 
15 sec. Protein concentrations were determined by a Bradford assay for which 1 µl pro-
tein lysate was added to 1 ml Bradford reagent (Sigma-Aldrich, Munich, Germany) and 
the optical density was measured at 595 nm. The total protein concentration was calcu-
lated based on a BSA standard curve. 
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Denaturing reduced protein electrophoresis 
The NuPAGE® system (Invitrogen™, LIFE TECHNOLOGIES, USA) was used for electropho-
retic separation of proteins. 50 µg total protein were mixed with appropriate volumes of 
NuPAGE® LDS sample buffer and NuPAGE® reducing agent according to the NuPAGE® 
user manual for denaturing gel electrophoresis with reduced protein samples. Samples 
were loaded on a NuPAGE® Novex 4-12% Bis-Tris-Gel and separated at 200V for 50 min in 
an electrophoresis apparatus filled with NuPAGE® MOPS SDS running buffer. 
 
Western blotting 
After electrophoretic separation proteins were transferred to PVDF or nitrocellulose 
membranes using the XCell II™ blot module (Invitrogen™, LIFE TECHNOLOGIES, USA). Pro-
tein gel, membrane, filter papers and blotting pads were assembled as shown in Figure 
2.1. All components were soaked in NuPAGE® transfer buffer with 10% methanol and the 
closed blot module was filled with transfer buffer for wet blotting. The protein transfer 
took place at 30V for 1h. Afterwards, successful transfer was verified by reversible Pon-
ceau S staining. 
 
 
Figure 2.1: Assembly of blotting pads, filter papers, protein gel 
and transfer membrane for western blotting (Invitro-
gen) 
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Immunological protein detection 
To prevent unspecific background binding, the membrane was incubated with 5% milk 
powder in TBS with 0.1% Tween-20 (TBS-T) for 1h at room temperature. For specific de-
tection of proteins, primary antibodies were diluted in 5% milk in TBS-T as listed in Table 
2.3. Primary antibody incubation was conducted at 4°C overnight. After three washes 
with TBS-T, the primary antibody was detected using a suitable horseradish peroxidase 
(HRP) coupled secondary antibody (dilutions are given in Table 2.3). Secondary antibody 
incubation took place for 1h at room temperature. The specific protein bands were visual-
ized by enhanced chemiluminescence (ECL) using the Amersham™ ECL plus reagent (GE 
Healthcare, Buckinghamshire, UK) or the SuperSignal West Femto chemiluminescent sub-
strate (Thermo Fisher Scientific Inc., Rockford, IL, USA) depending on signal intensity. The 
emerged light signal was detected using the ChemiDoc™ system (Biorad, Munich, Germa-
ny). 
Antigen Antibody Company Dilution 
Di-ras2 15557-1-AP Proteintech 1:1000 
β-Actin ab8224 Abcam 1:1000 
Mouse Ig 
Goat anti-Mouse 
HPR conjugated 
BD Pharmingen 1:5000 
Rabbit Ig 
Goat anti Rabbit HRP 
conjugated 
Sigma 1:20 000 
Table 2.3: Antibodies and dilutions used for western blotting analyses 
 
Blocking with immunizing peptide 
To determine if an antibody staining is specific or which band is specific if several bands 
occur, blocking of the antibody with the immunizing peptide was performed. For this, the 
blocking peptide was added to the diluted primary antibody to a final concentration of 1 
µg/ml and the solution was incubated with agitation for 30 min at room temperature. 
Then, the staining procedure was carried out as described above. 
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Stripping blots for reprobing 
In order to detect different targets in the same samples the primary and secondary anti-
bodies bound to the membrane were removed by a method called stripping. Whenever 
the primary antibody used for the second staining originated from a different species 
than the one used for the previous staining, a mild stripping method was used. The mem-
brane was incubated in stripping buffer containing 1.5% glycine, 0.1% SDS and 1% Tween 
20 (pH2.2) for 10 min, twice. After two 10 min washes with PBS and two 5 min washes 
with TBS-T the membrane was ready for blocking. When both antibodies originated from 
the same species, a harsher stripping protocol was used. This was done by incubating the 
membrane in a buffer containing 10% SDS, 0.5M Tris HCl (pH 6.8) and 0.8% β-
mercaptoethanol at 50°C for 30 min. The membrane was blocked after several washing 
steps with TBS-T. 
 
2.3.4. Fluorescence immunocytochemical double stainings 
Mouse primary hippocampal cell culture 
A 2 – 3 month old pregnant mouse (embryonic day 18 (E18), wild type, C57BL/6 back-
ground) was sacrificed by cervical dislocation or exposure to isoflurane (Forene®, Abbott, 
Illinois, USA). After opening the abdominal cavity the uterus with the embryos was trans-
ferred to a petri dish. The embryos were decapitated using a forceps and the heads were 
put in a new dish filled with pre-warmed HBSS buffer. The skin and the skull were cut 
along the middle vein and bent away to remove the brain. For dissection of the hippo-
campi the hemispheres were removed from diencephalon and brainstem. The meninges 
were removed carefully and hippocampi were dissected by cutting along the convex outer 
side using a forceps.  
 
All dissected hippocampi were transferred to pre warmed 0.05% Trypsin/EDTA and di-
gested at 37°C for 5 min. Hippocampi were washed with warm HBSS buffer twice. After 
removal of the HBSS, 2 ml of neurobasal medium were added. To separate the cells, hip-
pocampi were dissolved by pipetting up and down using a fire polished glass Pasteur pi-
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pette. Cells were counted using a Neubauer chamber. 800 000 cells were plated per 25 
cm2 culture flask and 25 000 cells per 2 cm2 cover slip. Culture flasks and cover slips were 
both poly-D-lysine coated. Cells were cultured for 5-30 days in an incubator at 37°C. For 
immunological staining cells were usually cultured for 12 days. 
 
Fixation and staining of cells 
For fixation, cells were washed with PBS and ice cold methanol was added. Cells were 
fixed for 20 min at -20°C. This was followed by three washes with PBS. Fixed cells can be 
stored in PBS at 4°C for several weeks. To prevent unspecific staining, cells were blocked 
for 2h at room temperature with PBS containing 2% normal goat serum (NGS). Primary 
antibody incubation was performed at 4°C overnight with antibodies diluted in 2% NGS in 
PBS as listed in Table 2.4. After washing with PBS, the cells were incubated with a 1:500 
dilution of fluorescence dye coupled secondary antibodies for 1-2h at room temperature. 
The cells were washed with PBS, rinsed with distilled water and afterwards coverslipped 
with Fluoro-Gel (EMS, Hatfield, PA, USA) containing a 1:1000 dilution of DAPI for nuclei 
staining. 
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Antigen Antibody Company Dilution 
Di-ras2 15557-1-AP Proteintech 1:500 
GFAP 
Monoclonal Anti-
GFAP clone G-A-5 
Sigma 1:2000 
Synyaptophysin 
Monoclonal Anti-
Synaptophysin 
Sigma 1:200 
MAP2 
Mouse Anti-MAP-2 
monoclonal 
Chemicon 1:500 
TH 
Mouse Anti-
Tyrosine Hydrox-
ylase 
Chemicon 1:500 
Calbindin 
Monoclonal Anti-
Calbindin D-28K 
Swant 1:500 
Parvalbumin 
Monoclonal Anti-
Parvalbumin 
Swant 1:500 
Rabbit Ig 
Alexa Fluor 488 goat 
Anti-Rabbit  
Sigma 1:400 
Mouse Ig 
Alexa Fluor 555 goat 
Anti-Mouse  
Sigma 1:400 
Table 2.4: Antibodies and dilutions used for immunocytological staining 
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3. Results 
3.1. Association studies 
3.1.1. KCNIP4 
Adult ADHD 
49 of 56 SNPs within or near the KCNIP4 gene passed quality control (Minor allele fre-
quency > 0.01, p value of χ² test for Hardy-Weinberg equilibrium (HWE) > 0.01, Call rate > 
80%) for association testing in 594 patients suffering from adult ADHD (aADHD) and 974 
healthy controls from Germany (Würzburg and Munich). Six SNPs showed a nominally 
significant association with aADHD with p values < 0.05 (see Table 3.1). In addition, eight 
markers were found to be associated with co-morbid disorders within the aADHD sample 
compared to controls (p values 0.0471 – 0.0067; Table 3.2). Haplotype testing revealed 
one (block 4) of the nine haploblocks (Figure 3.1) to be associated with the disease (p = 
0.0079). This block consists of the SNPs rs1388321, rs6447994, rs10516367, rs6850182, 
rs17557419 and rs16870168. The risk haplotype CACTCG of block 4 showed an odds ratio 
of 1.99. None of the SNPs within this haploblock showed an association with aADHD on 
the single marker level. The chromosomal position of all genotyped SNPs is depicted in 
Figure 3.2. 
 
SNP ID P value OR (allele) 95%-CI 
rs4697192 0.0166 1.23 (A) 1.0389 - 1.4653 
rs16870771 0.0349 1.51 (C) 1.0298 - 2.2211 
rs13110425 0.0092 1.24 (C) 1.0540 - 1.4525 
rs1349384 0.0490 1.19 (G) 1.0007 - 1.4184 
rs7356396 0.0138 1.28 (G) 1.0508 - 1.5472 
rs12646862 0.0147 1.27 (C) 1.0481 - 1.5371 
Table 3.1: Significant markers of the KCNIP4 gene of case control-based association testing for adult 
ADHD 
Six of the 49 tested SNPs showed an association with aADHD (p value < 0.05). OR = odds ratio; 
CI = confidence interval. 
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Phenotype SNP ID P value OR (allele) 95%-CI 
Anxiety disorder 
rs4697192 0.0201 1.40 (A) 1.0539 - 1.8525 
rs1388321 0.0169 1.39 (C) 1.0615 - 1.8326 
rs6850182 0.0383 1.28 (T) 1.0134 - 1.6137 
rs983071 0.0358 1.87 (A) 1.0426 - 3.3577 
rs16870771 0.0305 1.91 (C) 1.0625 - 3.4204 
Mood disorder 
rs4697192 0.0244 1.28 (A) 1.0328 - 1.5939 
rs6448034 0.0067 1.31 (C) 1.0782 - 1.5950 
rs17455886 0.0172 1.28 (C) 1.0448 - 1.5711 
rs13110425 0.0471 1.22 (C) 1.0025 - 1.4835 
Substance abuse 
disorder 
rs4697192 0.0169 1.35 (A) 1.0552 - 1.7261 
Table 3.2: SNPs that showed a nominally significant association with co-morbidities within the aADHD 
sample 
Eight markers were found to be associated with co-morbid disorders. rs4697192 was associated 
with anxiety disorder, mood disorder and substance abuse disorder. The other seven markers 
were associated with anxiety disorder or mood disorder. 
 
 
 
Figure 3.1:  Haploblock structure of the KCNIP4 gene 
Due to the linkage disequilibrium between SNPs, the KCNIP4 gene showed a haploblock struc-
ture consisting of nine blocks. The CACTCG haplotype of block 4 was nominal significant asso-
ciated with aADHD (p = 0.0079; OR = 1.9870). 
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Childhood ADHD 
Pedigree disequilibrium testing for 51 SNPs which passed quality check was performed 
with genotyping data gained from 171 families (113 trios, 43 quartets and 15 multi sib-
ling) consisting of 592 individuals in total. Two SNPs indicated a nominally significant as-
sociation with ADHD (rs16869915 p = 0.0477 and rs358834 p = 0.0411). Nine markers 
showed an over-transmission of one allele for co-morbid disorders, but only two of them 
acquired a sufficient significance level (rs11726872: learning disability p = 0.0038; 
rs6447994: oppositional defiant disorder p = 0.0023). 
 
Personality disorders 
To investigate the possible role of KCNIP4 in PD, 48 SNPs in 630 cases and 974 controls 
were genotyped. After eight markers did not fulfill quality criteria, 40 SNPs were tested 
for an association with cluster B and cluster C PD. Six SNPs were found to be associated 
with cluster B and four SNPs with cluster C PD. For the markers rs1425326, rs7356396 and 
rs12646862 risk alleles for both cluster B and C PD were identified (Table 3.3).  
Phenotype SNP ID P value OR (allele) 95% Cl 
Cluster B 
rs11726872 0.02639 1.33 (C) 1.0344 - 1.7202 
rs1425326 0.00910 1.35 (T) 1.0769 - 1.6849 
rs6448034 0.03561 1.20 (C) 1.0123 - 1.4220 
rs983071 0.04367 1.43 (A) 1.0102 - 2.0173 
rs7356396 0.03393 1.22 (G) 1.0151 - 1.4616 
rs12646862 0.01907 1.24 (C) 1.0361 - 1.4875 
Cluster C 
rs2291530 0.03311 1.87 (T) 1.0515 - 3.3296 
rs1425326 0.03552 1.40 (T) 1.0229 - 1.9061 
rs7356396 0.00428 1.40 (G) 1.1123 - 1.7716 
rs12646862 0.00849 1.36 (C) 1.0823 - 1.7171 
Table 3.3:  Markers of the KCNIP4 gene associated with cluster B and cluster C PD 
The markers rs1425326, rs7356396 and rs12646862 were found to be associated with cluster B 
as well as with cluster C PD. 
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Figure 3.2: Chromosomal position of the genotyped KCNIP4 SNPs  
The chromosomal position of the SNPs is plotted against the negative logarithmic p values for 
an association with aADHD (blue diamonds), aADHD combined subtype only (red squares), 
cADHD (green triangles), cluster B PD (grey cross) and cluster C PD (light blue crosses). The 
threshold for nominal significance at 1.3 is indicated by a black line. Most SNPs are situated in 
the 5´region or the first intron of the gene depending on the variant. 
 
3.1.2. CDH13 
Adult ADHD 
In the initial study 86 SNPs were genotyped in 602 adult ADHD patients and 422 healthy 
controls from Germany. 73 SNPs survived quality control and passed through case con-
trol-based association testing. Ten markers showed p values indicating an association of 
the CDH13 gene with aADHD (Table 3.4). Bonferroni correction for 73 tests leads to a sig-
nificance threshold of p = 0.0007. rs11642219 is the only SNP showing a significant asso-
ciation after correction. Twelve haploblocks could be defined of which block 4 consisting 
of the markers rs4591132, rs9888896, rs7189859, rs7197530, rs2228685 revealed a pro-
tective haplotype (TTGTT) after statistical evaluation (p = 0.0394, OR = 0.40). 
 
To replicate this, genotyping of 58 CDH13 SNPs and association testing in three samples 
from the IMpACT consortium consisting of 1018 aADHD cases and 1384 controls from The 
Netherlands, Norway and Spain was performed. Two markers (different from the ten 
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which showed an association with the disease in the initial study) revealed a nominal sig-
nificance in the IMpACT sample (rs 16958788 p = 0.0070 and rs16961122 p = 0.0116).  
 
SNP ID 
German discovery 
sample 
IMpACT replication 
sample 
Pooled data 
P 
value 
OR  
(allele) 
95%-
CI 
P  
value 
OR  
(allele) 
95%-
CI 
P 
value 
OR  
(allele) 
95%-
CI 
rs4445897 0.0119 1.41 (T) 
1.07 
– 
1.84 
0.2694 1.10 (C) 
0.93 
– 
1.31 
0.8069 1.02 (T) 
0.88 
– 
1.17 
rs12925602 0.0133 1.45 (G) 
1.08 
– 
1.96 
0.1158 1.17 (A) 
0.96 
– 
1.43 
0.9430 1.01 (G) 
0.85 
– 
1.19 
rs16958148 0.0286 1.32 (G) 
1.03 
– 
1.68 
0.4631 1.06 (T) 
0.90 
– 
1.25 
0.5438 1.04 (G) 
0.91 
– 
1.19 
rs4591132 0.0032 1.33 (C) 
1.10 
– 
1.61 
0.3866 1.05 (C) 
0.93 
– 
1.19 
0.0204 1.13 (C) 
1.02 
– 
1.25 
rs2228685 0.0399 1.23 (T) 
1.01 
– 
1.51 
0.0749 1.11 (T) 
0.99 
– 
1.25 
0.0099 1.14 (T) 
1.03 
– 
1.25 
rs4077621 0.0171 1.41 (A) 
1.06 
– 
1.88 
0.0131* 1.29 (C) 
1.05 - 
1.57 
0.5254 1.05 (C) 
0.90 
– 
1.23 
rs17211336 0.0156 1.39 (A) 
1.06 - 
1.81 
0.1610 1.12 (G) 
0.95 - 
1.32 
0.9434 1.01 (A) 
0.87 
– 
1.16 
rs11642219 0.0003 1.62 (G) 
1.25 - 
2.11 
0.7311 1.03 (G) 
0.85 - 
1.26 
0.0150 
1.22 
(G) 
1.04 
– 
1.42 
rs153653 0.0055 1.43 (C) 
1.11 - 
1.85 
0.5339 1.06 (C) 
0.89 - 
1.26 
0.0355 1.17 (C) 
1.01 -
1.35 
rs692612 0.0010 1.45 (G) 
1.16 - 
1.80 
0.8950 1.01 (G) 
0.87 - 
1.17 
0.0524 1.13 (G) 
1.00 
– 
1.28 
Table 3.4:  Significant markers of the CDH13 gene in the case control-based association study on aADHD 
Ten markers showed an association with aADHD in the initial sample from Germany. The associ-
ation of rs11642219 is significant even after correcting for multiple testing (significance thresh-
old = 0.0007). The only SNP which had a p value < 0.05 in the IMpACT replication sample had to 
be excluded due to HWE < 0.01 (indicated by a star). Bold face, significant findings in the pooled 
samples. The pooled analysis of all 1620 cases and 1806 controls revealed four SNPs with nomi-
nally significant p values  
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The sole SNP among the initially associated ones which had a p value < 0.05 in the replica-
tion study, had to be excluded due to HWE < 0.01. However, in a pooled analysis of all 
1620 cases and 1806 controls four of the SNPs had nominally significant p values (Table 
3.4). A two stage design meta-analysis revealed marker rs11642219 to be associated with 
ADHD robust to correction (empirical p value = 0.00014; corrected p value = 0.0102). 
 
  
  
Figure 3.3:  Meta-analyses on the effects of four risk alleles found in the CDH13 gene 
Odds ratios of the risk alleles of rs4591132, rs2228685, rs11642219 and rs153653 in the four in-
dependent aADHD samples and in summary 
 
Childhood ADHD 
To investigate the role of CDH13 in childhood ADHD, 170 families from Franconia (112 
trios, 43 quartets and 15 multi sibling) were genotyped. This family-based association 
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study revealed six markers which showed an allele over-transmission to affected children 
(see Table 3.5). Only one of those SNPs (rs4077621) was found to be associated with 
ADHD in the German adult sample, as well. No haplotype was found to be associated with 
cADHD in this sample. 
For a replication of the single marker associations found in the families from Würzburg, a 
second independent family-based sample from Homburg (Germany) was examined. Pedi-
gree disequilibrium testing in 142 trios resulted in three SNPs with an over-transmitted 
allele (rs7198517, rs13338647, rs16961122) with p values ranging from 0.0357 to 0.0184 
different from those identified in the initial family sample. There was no overlap of the 
SNPs identified in this replication sample with the associated SNPs in the aADHD sample. 
SNP ID 
Over transmission PDT 
Allele Rate (%) P value 
rs1019959 C 52.7 0.0168 
rs4077621 C 51.4 0.0326 
rs12716966 C 52.4 0.0413 
rs8182163 T 52.0 0.0413 
rs10514575 A 51.1 0.0389 
rs2326025 G 51.8 0.0367 
Table 3.5:  Over transmitted alleles of CDH13 in the family-based cADHD sample from Würzburg 
Six SNPs showed over transmission of one allele to affected children. None of these markers 
showed an over transmission in the replication sample from Homburg. 
 
Comorbid conditions in the aADHD and the cADHD samples 
As the cADHD samples from Germany and the aADHD samples from Germany and The 
Netherlands were also assessed for comorbid conditions, the genotyping data have been 
tested for associations with those co-morbidities, as well. 
 
In the German aADHD sample, 20 SNPs associated with different comorbid conditions 
could be identified (p values 0.0432 – 0.0011). Twelve SNPs of which five were identical to 
those encountered in the sample from Germany were found in the Dutch sample to be 
associated with comorbidities in ADHD with p values of 0.0492 to 0.0006. Except of one 
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marker (rs16958148), all SNPs that have been identified as associated with aADHD in the 
initial sample showed an association with one or even more comorbid disorders, too. 
 
For cADHD, 15 markers in the sample from Würzburg and eight in the Homburg sample 
were associated with comorbid disorders (mainly conduct disorder, oppositional defiant 
disorder and depression). None of those markers was found to be associated with ADHD 
within the same sample. Though, rs13338647 was associated with depression in the 
Würzburg sample and with ADHD in the replication sample, rs1019959 and rs8182163 
were associated with ADHD in the initial study and with conduct disorder in the replica-
tion. 
Association of CDH13 with personality disorders 
To test whether CDH13 may be involved in PD which are known to be related to ADHD, 
case control-based association testing of a PD sample consisting of 629 patients suffering 
from cluster B or cluster C PD was conducted. The single marker association findings are 
listed in Table 3.6. 
 
Three out of 40 analyzed SNPs showed nominally significant association with both cluster 
B and cluster C PD. One SNP (rs16958148) was found to be associated with cluster C dis-
orders and showed tendencies of an association with cluster B disorders with a p value 
slightly exceeding the significance threshold (p = 0.0552). Bonferroni correction for 40 
tests results in a significance threshold of p = 0.00125 which is slightly exceeded by 
rs692612 with a p value for association with cluster B PD of 0.0013. The association found 
for rs11642219 with cluster B PD withstands correction. 
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 PD Cluster B PD Cluster C 
SNP ID 
P  
value 
OR 
(allele) 
95%-CI 
P  
value 
OR 
(allele) 
95%-CI 
rs16958148 0.0552 n.a. n.a. 0.0335 1.40 (G) 
1.0266 - 
1.9134 
rs11642219 0.00001 1.90 (G) 
1.4269 - 
2.5197 
0.0071 1.60 (G) 
1.1360 - 
2.2489 
rs16961669 0.0261 1.56 (C) 
1.0546 - 
2.3172 
0.0041 2.34 (C) 
1.3074 - 
4.1852 
rs692612 0.0013 1.49 (G) 
1.1688 - 
1.9057 
0.0173 1.45 (G) 
1.0672 - 
1.9585 
Table 3.6:  Results of case control association analyses of CDH13 with PD 
Four SNPs showed a nominally significant association with cluster C PD. Three out of those four 
markers also showed an association with cluster B PD. rs11642219 is significant even after cor-
rection for multiple testing (significance threshold after correction = 0.00125). 
 
 
Figure 3.4: Chromosomal distribution of the genotyped CDH13 SNPs 
The chromosomal position of the SNPs is plotted against the negative logarithmic p values for 
an association with cADHD in the initial sample from Würzburg (blue diamonds), cADHD in the 
replication sample from Homburg (orange dots), aADHD in the initial sample from Germany (red 
squares), aADHD in the IMpACT sample from Norway, The Netherlands and Spain (green trian-
gles), cluster B PD (grey cross) and cluster C PD (light blue crosses). The threshold for nominal 
significance at 1.3 is indicated by a black line. Most of the initial found SNPs for aADHD and PD 
are clustered in the 3´region of the gene or the 3´UTR. 
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3.1.3. DIRAS2 
Adult ADHD 
In the German aADHD sample 600 patients were compared to 420 healthy controls. Four 
out of 12 SNPs tested for an association with the disease showed a nominal significance 
(Table 3.7). The replication of this single marker association finding in the IMpACT sample 
consisting of 1035 aADHD patients and 1381 controls from The Netherlands, Norway and 
Spain failed. Nevertheless, meta-analyses for the best four SNPs of the discovery sample 
in all 1635 patients and 1801 controls revealed the marker rs1412005 to be associated 
with adult ADHD with a nominal p value of 0.0437 (adjusted for five tests p = 0.175). The 
effects of the T risk allele of this marker in the four independent aADHD samples and in 
summary are shown in Figure 3.5. 
 
SNP ID 
German discovery 
sample 
IMpACT replication 
sample 
Pooled data 
P  
value 
OR  
(allele) 
95%-
CI 
P  
value 
OR  
(allele) 
95%-
CI 
P  
value 
OR  
(allele) 
95%-
CI 
rs7854469 0.0394 1.40 (T) 
1.02 - 
1.93 
0.0720 1.19 (A) 
0.98 - 
1.43 
0.6023 1.04 (A) 
0.89 - 
1.23 
rs16906711 0.0453 1.97 (G) 
1.01 - 
3.81 
0.7288 1.07 (C) 
0.74 - 
1.55 
0.4271 1.14 (G) 
0.83 - 
1.55 
rs1331503 0.0125 1.27 (A) 
1.05 - 
1.54 
0.5812 1.03 (A) 
0.92 - 
1.17 
0.0678 1.10 (A) 
0.99 - 
1.22 
rs1412005 0.0182 1.29 (T) 
1.04 - 
1.58 
0.3785 1.06 (T) 
0.93 - 
1.21 
0.0437 1.12 (T) 
1.00 - 
1.25 
Table 3.7: Significant SNPs of the DIRAS2 gene of case control-based association analysis for aADHD 
Four SNPs were nominally significant associated with aADHD in the discovery sample. None of 
those single marker association findings could be replicated in the IMpACT sample. Meta-
analysis for the four SNPs revealed rs1412005 to be associated with aADHD. 
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Figure 3.5: Effects of the rs1412005 T risk allele 
Odds ratios of the T risk allele of 
rs1412005 in the four independent 
aADHD samples and in summary 
 
For each of the two haplotype blocks of the DIRAS2 gene (see Figure 3.6) one risk haplo-
type could be identified in the aADHD sample from Germany (block 1: GTGGGT p = 0.006; 
block 2: ACGCTT p = 0.033). Association testing for the haplotype ACGCTT from block 2 in 
the IMpACT sample replicated the significant finding from the discovery sample (p = 
0.026). Meta-analyses of this risk haplotype revealed an association with an increased risk 
for aADHD and this effect was statistically significant even after adjusting for multiple 
testing (p=0.00028, p value adjusted for five tests: 0.001, OR=1.45, 95% CI: 1.19-1.77; 
Figure 3.7). This haplotype contains the T allele of SNP rs1412005. 
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Figure 3.6: Haploblock structure of the DIRAS2 gene 
Linkage disequilibrium (LD) plot of DIRAS2. rs1017753 is the last SNP of 
block 1, while rs1331503 is the first SNP of block 2. rs7854469 and 
rs16906711 are associated with aADHD; rs1331503 with aADHD and 
personality domains; rs7848810 with cADHD and personality domains; 
and rs1412005 with aADHD, bipolar disorders, Cluster C PD and per-
sonality domains; a risk haplotype for aADHD was identified for block 2. 
 
 
Figure 3.7:  Effects of the risk haplotype of block 
2 in the DIRAS2 gene 
Odds ratios of the ACGCTT haplotype 
in the four independent aADHD sam-
ples and in summary 
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Childhood ADHD 
To extend the association findings for DIRAS2 to cADHD, 166 independent nuclear fami-
lies with offspring affected by cADHD were analyzed. The rs1412005 T allele was not sig-
nificantly over-transmitted (p=0.65), but the C allele of the neighboring SNP rs7848810, 
which is also located in the promoter region, was (p=0.046, transmission rate: 53%). Hap-
lotype analysis provided evidence of significant association of the haplotype block 2 
(p=0.0231) with a p value for the specific haplotype ACGCTT slightly exceeding 0.05 
(p=0.0692, frequency among transmitted versus non-transmitted haplotypes: 11% versus 
6.5%, OR=2.01, 95% CI: 0.80-5.00). rs7848810 was also associated with co-morbid dyslex-
ia (p=0.015).  
 
Related disorders and personality traits 
To check for possible associations of DIRAS2 with other psychiatric disorders known to be 
related to ADHD, SNP genotyping of a bipolar disorder sample and a PD samples (cluster B 
and cluster C) was conducted. 
Marker rs1412005 was found to be nominally significantly associated with bipolar disor-
ders and cluster B PD. Also, a tendency (p = 0.0855) for an association with cluster C PD 
could be observed for this SNP (Table 3.8). The T allele of this SNP represents the risk al-
lele for all three disorders (OR = 1.26 – 1.32), which is consistent with the findings in 
ADHD. 
SNP ID 
Biplolar Cluster B Cluster C 
P  
value 
OR 
(allele) 
95%-
CI 
P  
value 
OR 
(allele) 
95%-
CI 
P  
value 
OR 
(allele) 
95%-
CI 
rs16906711 0.4935 
1.32 
(G) 
0.59 - 
2.94 
0.0454* 
1.95 
(G) 
1.01 - 
3.75 
0.0220* 
2.33 
(G) 
1.13 - 
4.80 
rs1412005 0.0256 1.32 (T) 
1.03 - 
1.67 
0.0305 1.27 (T) 
1.02 - 
1.59 
0.0855 1.26 (T) 
0.97 - 
1.64 
Table 3.8:  DIRAS2 SNPs associated with disorders related to ADHD 
Nominally significant p values are shown in bold letters 
*pHWE=0.001 
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The aADHD and PD samples recruited in Würzburg had also been assessed for personality 
dimensions using the NEO-PI R (testing for Neuroticism, Extraversion, Openness to Expe-
rience, Agreeableness, Conscientiousness) and the TPQ (Novelty Seeking, Harm Avoid-
ance, Reward Dependence). This enabled an additional investigation to clarify whether 
personality scores may also be affected by DIRAS2 variants. The nominally significant as-
sociation results are depicted in Table 3.9. In the aADHD sample, p values < 0.05 were 
found for Neuroticism, Extraversion, Agreeableness, Conscientiousness and Harm Avoid-
ance. The three SNPs rs1331503, rs1412005 and rs689687, which were associated with 
these personality traits, are located in haplotype block 2 and the transcriptional control 
region of the gene. In the PD sample, nominal evidence of association was found for Ex-
traversion, Agreeableness, Conscientiousness, Novelty Seeking and Harm Avoidance (p 
values between 0.008 and 0.040). In comparison to the aADHD sample, different SNPs 
showed association in this sample and most of them are located in the haplotype block 1. 
However, rs7854469 was associated with both aADHD and the ADHD-relevant personality 
trait Extraversion in PD (p=0.0075, Table 3.9). Also, the aADHD associated SNP rs7848810 
 
Figure 3.8: Chromosomal position of the genotyped DIRAS2 SNPs 
The chromosomal distribution of the SNPs is plotted against the negative logarithmic p values 
for an association with cADHD (blue diamonds), aADHD in the initial sample from Germany (red 
squares), aADHD in the IMpACT sample from Norway, The Netherlands and Spain (green trian-
gles), cluster B PD (grey cross), cluster C PD (light blue crosses) and bipolar disorders (orange 
dots). The threshold for nominal significance at 1.3 is indicated by a black line. The SNPs associ-
ated with aADHD are clustered at the protein coding exon 2 of the DIRAS2 gene and at the pro-
moter region. 
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was associated with Novelty Seeking (p=0.0396) and Conscientiousness (p=0.0123) in the 
PD sample (Table 3.9).  
 
Personality 
trait 
SNP 
ID 
aADHD cases PD patients 
P value Beta (allele) Se P value Beta (allele) Se 
NEO-N 
rs1331503 0.0241 3.51 (A) 1.55 0.3113 1.72 (A) 1.70 
rs689687 0.0327 4.14 (C) 1.93 0.5747 1.15 (C) 2.05 
NEO-E 
rs7854469 0.4172 2.07 (A) 2.55 0.0075 6.32 (T) 2.36 
rs1331503 0.0065 3.68 (T) 1.35 0.6695 0.59 (T) 1.38 
rs1412005 0.0088 3.83 (G) 1.46 0.7600 0.44 (T) 1.42 
NEO-A 
rs7854469 0.8963 0.26 (T) 1.96 0.0116 4.24 (A) 1.67 
rs2297354 0.2065 4.78 (C) 3.78 0.0288 10.03 (C) 4.57 
rs689687 0.0284 2.80 (C) 1.28 0.2645 1.28 (T) 1.15 
NEO-C 
rs690111 0.9152 0.17 (T) 1.60 0.0448 2.87 (T) 1.43 
rs1331503 0.0173 3.24 (T) 1.36 0.1876 1.77 (T) 1.34 
rs7848810 0.9051 0.18 (C) 1.52 0.0123 3.49 (A) 1.39 
rs1412005 0.0135 3.61 (G) 1.46 0.1013 2.26 (G) 1.38 
rs689687 0.0043 4.84 (T) 1.69 0.1166 2.50 (T) 1.59 
TPQ-NS 
rs7854469 0.8075 0.16 (A) 0.65 0.0224 1.35 (T) 0.59 
rs7848810 0.3585 0.35 (A) 0.38 0.0396 0.73 (C) 0.36 
TPQ-HA 
rs7868194 0.1634 0.62 (A) 0.45 0.0126 1.08 (G) 0.43 
rs1017753 0.0897 0.74 (C) 0.43 0.0257 0.95 (T) 0.43 
rs1331503 0.0023 1.30 (A) 0.42 0.7309 0.16 (A) 0.46 
rs1412005 0.0018 1.43 (T) 0.46 0.7284 0.17 (T) 0.48 
rs689687 0.0033 1.54 (C) 0.52 0.6540 0.25 (T) 0.55 
Table 3.9:  Results of association analysis for quantitative personality traits in the aADHD and the PD 
sample. 
Nominal significant p values are printed in bold. NEO-E = Extraversion; NEO-A = Agreeableness; 
NEO-C = Conscientiousness; TPQ-NS = Novelty Seeking; TPQ-HA = Harm Avoidance. 
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3.2.  Diras2 expression studies 
3.2.1. Expression of Diras2 during development 
Diras2 expression levels were determined by qPCR using total RNA isolated from mouse 
brains at different developmental stages as described in 2.3.1. Samples were grouped as 
followed: Prenatal (n = 6; embryonic day 11, 13 and 15), early postnatal (n = 12; postnatal 
days 0, 1, 2, 4, 5 and 7), late postnatal (n = 12; postnatal days 9, 10, 11, 13 and 15), ado-
lescence (n = 6; postnatal days 16, 17, 18, 19, 22 and 23) and adult (n = 5; aged two to 
four months). Normalized expression levels showed a significant increase in Diras2 ex-
pression in the mouse brain during early developmental stages. After significant group 
differences (p < 0.05) were detected using the Kruskal-Wallis test, significant increases in 
expression levels were found between the prenatal and the early postnatal (P 0 – 7) 
group and between the early postnatal and the late postnatal (P 9 – 15) group using the 
Mann-Whitney test (p < 0.0083; significance threshold adjusted for six tests). From the 
late postnatal development to adulthood, no differences in Diras2 expression in the 
mouse brain could be observed (see diagram in Figure 3.9).  
 
 
Figure 3.9: Diras2 expression levels during brain development 
Normalized expression levels of Diras2 in the mouse brain 
at different developmental stages determined by qPCR. A 
significant increase in expression levels could be observed 
between the prenatal and the early postnatal group and 
between the early and late postnatal group. 
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3.2.2. Expression of DIRAS2 in the human brain 
The expression of DIRAS2 in the human brain was investigated by conducting qPCR anal-
yses using purchased pooled total RNA isolated from different human brain regions. The 
highest DIRAS2 expression was found in the hippocampus followed by the cerebral cortex 
and the cerebellum. The expression levels in the caudate nucleus, putamen and the raphe 
nuclei containing regions medulla oblongata and pons were strikingly lower. 
 
 
Figure 3.10: Expression of DIRAS2 in the human brain 
Normalized expression levels of DIRAS2 in different human brain regions. High-
est DIRAS2 expression was observed in the hippocampus, the cerebral cortex 
and the cerebellum. CC = cerebral cortex; NC = caudate nucleus; Pu = putamen; 
Hip = hippocampus; CB = cerebellum; MO = medulla oblongata; Po = pons. 
 
3.2.3. Expression of Diras2 in the mouse brain 
To investigate the expression pattern of Diras2 in the mouse brain, in situ hybridization 
was performed as described in 2.3.2. The results of the detection of the cRNA probe spe-
cific for the Diras2 mRNA in the mouse brain are shown in Figure 3.11.  
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In the olfactory bulb, Diras2 expression is mainly localized in the mitral cell layer (Figure 
3.11 A). The deep cellular zone of the anterior olfactory nucleus as well as the orbital cor-
tex showed a notable expression of the gene (Figure 3.11 B). In the posterior regions of 
the cerebral cortex a strong staining of distinct cortical layers, probably layers V and VI 
and layers II and/or III, could be observed (Figure 3.11 D,E and H). In addition, Diras2 is 
strongly expressed in the piriform cortex, the amygdala, the hippocampus and the granu-
lar cell layer of the cerebellar cortex. Expression in the amygdala seems to be localized in 
the basolateral nucleus exclusively (Figure 3.11 E and G). In the hippocampus, a very in-
tense staining is visible in the dentate gyrus, CA3 and CA1 region (Figure 3.11 E and F). 
Isolated Diras2 positive spots in the hilus may correspond to interneurons located in this 
area. Besides those areas showing a very strong Diras2 signal, a weaker or more punctual 
expression could also be observed in the striatum (caudate putamen), the lateral septal 
nucleus (Figure 3.11 D), the substantia nigra, the parafascicular thalamic nucleus (Figure 
3.11 I) and the locus coeruleus (Figure 3.11 J). 
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Figure 3.11: In situ hybridization specific to Diras2 on native mouse brain slices 
Visualization of Diras2 mRNA on mouse brain cryosections of 10 µm thickness using in situ hy-
bridization. Highest expression levels can be observed in the cerebral cortex, the amygdala, the 
hippocampus and the cerebellar cortex. 2Cb = 2nd Cerebellar lobule; 4&5Cb = 4&5th Cerebellar 
lobule; AON = anterior olfactory nucleus; BLA = basolateral amygdaloid nucleus; CA1 = field CA1 
of hippocampus; CA3 = field CA3 of hippocampus; cc = corpus callosum; cp = cerebral peduncle; 
CPu = caudate putamen (striatum); DG = dentate gyrus; Hip = hippocampus; La = lateral amyg-
daloid nucleus; LC = locus coeruleus; LO = lateral orbital cortex; LSD = lateral septal nucleus, 
dorsal part; Mi = mitral cell layer of the olfactory bulb; PF = parafascicular thalamic nucleus; Pir 
= piriform cortex; SNR = substantia nigra 
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3.2.4. Expression of Di-ras2 in different cell types 
To detect the Di-ras2 protein, at first a purchased antibody was tested for specific binding 
in western blotting analyses using human and mouse brain lysates. After ensured anti-
body specificity, the human cell lines A172, SK-N-SH, U373 and HEK293 were tested for 
Di-ras2 occurrence. In all of the four investigated human cell lines there was no or just a 
weak Di-ras2 signal (Figure 3.12 A). In addition, mouse hippocampal primary cells were 
examined at different times after seeding. As primary cells showed the highest protein 
expression after 12 days in culture (Figure 3.12 B), cells were cultured for 12 days for fluo-
rescence double staining. 
 
A 
 
B 
 
Figure 3.12: Western blot analyses of Di-ras2 
Detection of the Di-ras2 protein after electrophoretic separation of proteins A) in lysates of the 
four human cell lines A172, SK-N-SH, U373; HEK293, two different human brain lysates and a 
murine brain lysate; B) in murine brain lysate and four lysates of murine hippocampal primary 
cells harvested at different times after seeding. A172 = glioblastoma cell line; SK-N-SH = neuro-
blastoma cell line; U373 = astrocytoma cell line; HEK293 = immortalized human embryonic kid-
ney cells; kD = kilo Dalton; PC = murine hippocampal primary cells; d = days after seeding. 
 
To investigate in which cell types Di-ras2 is present, mouse hippocampal primary cells 
were fixed and stained after 12 days in culture. The antibody against Di-ras2 was detected 
with an alexa488 labeled secondary antibody. Antibodies against several cell markers 
were detected using an alexa555 coupled secondary antibody. Double staining against Di-
ras2 and the glial fibrillary acidic protein (GFAP), which is a glia cell marker, showed no 
overlap in expression, indicating that Di-ras2 is not present in glia cells (Figure 3.13 A). Di-
ras2 is found in microtubule associated protein 2 (MAP2) positive cells. Since MAP2 is a 
neuronal marker, this result leads to the assumption that Diras2 is expressed in neurons. 
Other than the MAP2 staining, the Di-ras2 staining is as well present in the axonal and 
dendritic branches far off the cell body (Figure 3.13 B). Simultaneous detection of Di-ras2 
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and Synaptophysin, a synaptic vesicle glycoprotein, is shown in Figure 3.13 C. This staining 
also indicates expression in the same cell type, but not with exactly the same subcellular 
localization, as Di-ras2 is located rather at the cell soma then at the synapses. 
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Figure 3.13: Immunocytological double staining of primary cells 
Murine hippocampal primary cells were stained with the Di-ras2 antibody (green) and antibod-
ies against cell markers (red). Yellow color in the merged pictures indicates a co-expression. A) 
No co-expression of Di-ras2 with GFAP could be found; B) MAP2 stained cells are Di-ras2 posi-
tive; C) Detection of Di-ras2 and Synaptophysin in the same cells. GFAP = glial fibrillary acidic 
protein; MAP2 = microtubule associated protein 2 
 
To check whether Di-ras2 is present in all neuronal cells or only in specific neuronal cell 
types, additional double staining against Di-ras2 and Parvalbumin, Calbindin and Tyrosine 
Hydroxylase were conducted (Figure 3.14). Parvalbumin and Calbindin are both markers 
for GABAergic interneurons. While Parvalbumin occurs in cells with thick myelinated ax-
ons, Calbindin antibodies mainly label cells with thin, unmyelinated axons (Celio, 1990). 
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The enzyme Tyrosine Hydroxylase (TH) is responsible for the synthesis of dihydroxy-
phenylalanine (DOPA) which is the precursor molecule for dopamine. As dopamine is a 
precursor for norepinephrine and epinephrine, TH is a marker for dopaminergic, nora-
drenergic and adrenergic neurons. All three of the marker proteins were found in Di-ras2 
positive cells (see Figure 3.14 B). Hence, Di-ras2 protein could be detected in all neuronal 
subtypes investigated so far. 
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Figure 3.14: Immunocytochemical double staining of mouse hippocampal primary cells 
Staining against Di-ras2 is shown in green, detection of Parvalbumin (A), Calbindin (B) and TH (C) 
is represented in red. All cells positive for one of the three markers (A-C) also showed Diras2 
expression. TH = tyrosine hydroxylase. 
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4. Discussion 
The present work aims to further examine three candidate genes which are potentially 
involved in the genetic predisposition towards ADHD.  
4.1. KCNIP4 
The KCNIP4 gene was considered as a potential candidate gene for ADHD because its 
chromosomal locus on chromosome 4 emerged from a GWAS of cADHD, a GWAS of 
aADHD and a GWAS of PD. For the candidate gene-based association studies, tagging 
SNPs of the exons and their flanking regions as well as tagging SNPs situated in the pro-
moter region and the 3´UTR of the KCNIP4 gene have been genotyped in an adult ADHD 
sample, a family-based childhood ADHD sample and a PD sample. On the single marker 
level, six out of 49 SNPs were found to be associated with aADHD. The two markers which 
showed an association with childhood ADHD were different from those found in the adult 
sample with one marker (rs16869915) being the only associated one located in the 3´UTR 
of the gene. However, due to the p values calculated for those two markers barely ex-
ceeding the nominal significance threshold and the given likelihood for false positive re-
sults, the association finding of KCNIP4 with childhood ADHD seems not to be very robust. 
Two SNPs (rs7356396 and rs1264862) were found to be nominally significant associated 
with aADHD and cluster B and cluster C PD. Additionally, two markers which showed an 
association with cluster B PD were also found to be associated with co-morbid disorders 
in aADHD (rs6448034, mood disorders; rs983071, anxiety disorders) indicating a role of 
KCNIP4 not only in ADHD but also in personality and other co-morbid disorders. Noticea-
bly, the major part of the SNPs associated with one of the investigated diseases is located 
in intron1 or the 5´upstream sequence of the KCNIP4 gene depending on the isoform 
(Figure 3.2). This is true for nine out of 13 associated SNPs, whereas the genotyped SNPs 
are allocated across all exons and flanking sequences of the gene. The first intron of the 
KCNIP4 gene comprises up to 1,065,861 base pairs, depending on the isoform. Many pre-
dicted transcription factor binding sites can be found in this region. For example the 
rs1264862 risk allele identified for aADHD and cluster B and C PD leads to a loss of a 
Homeobox B9, a TATA box and a Pax 2/5/8 binding site but gives rise to a new 
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Hmx2/Nkx5-2 homeodomain transcription factor binding site. Pax and homeodomain 
transcription factors are known to be essential for the control of the genesis of the mid-
brain and cerebellum in the vertebrate embryo (Pfeffer 2000). Therefore, it is conceivable 
that KCNIP4 expression or rather the expression of certain KCNIP4 isoforms through al-
ternate promoters, transcription start sites or splicing is altered in risk allele carriers and 
may have an impact on neurodevelopment. There is not much known about the expres-
sion and different functions of the six described KCNIP4 isoforms. Cell type specific differ-
ential expression of two of the isoforms has been reported. Additionally, these isoforms 
seem to differ in their rate of potassium current inactivation (Baranauskas, 2004) and 
thus may cause differences in the neuronal excitability of the cells in which they are ex-
pressed. The functions and expression patterns of the other four KCNIP4 isoforms remain 
unknown. Hence, further investigation of expression patterns, transcriptional and transla-
tional regulation as well as functional analyses of the different isoforms of this candidate 
gene are clearly needed. 
 
It has to be noted that the association findings presented in this work are nominally sig-
nificant and do not withstand correction for multiple testing, rendering the positive asso-
ciation data preliminary at best. Moreover, as only one sample each was investigated for 
aADHD, cADHD and PD, a replication of the association findings in additional independent 
samples is necessary.  
However, the described association study results together with the existing GWAS results 
provide evidence that KCNIP4 is a promising candidate gene not only for aADHD but also 
for PD. This assumption is further supported by the possible function of KCNIP4 via Nurr1 
in the development of dopaminergic neurons in the midbrain that regulate motor control 
as hyperactivity is a core symptom of the hyperactive/impulsive and of the combined sub-
type of ADHD. 
4.2. CDH13 
The CDH13 gene represents one of the most promising candidate genes in the genetics of 
ADHD. The chromosome 16q24 locus which harbors this gene was found to be associated 
with ADHD in several linkage scans and GWAS. Moreover, CDH13 has been found to be 
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associated with alcoholism, substance abuse and schizophrenia. The functions of Cadher-
in13 in cell proliferation and survival via the PI3K/Akt/mTOR pathway and in cell adhesion 
and polarization as well as in cell migration underline the likelihood of its role in neurode-
velopment. To confirm an association of CDH13 with ADHD and related psychiatric disor-
ders, a SNP fine-mapping of the gene in seven independent samples was conducted. For 
the initial German aADHD sample, the most significant associated SNPs are clustered at 
the 3´region of the gene (see Figure 3.4). A total of 10 SNPs was found to be nominally 
significant associated with aADHD. The replication of those single marker findings in three 
additional independent aADHD samples was not successful. However, a meta-analytic 
approach for the ten top SNPs of the first association study revealed four SNPs to be as-
sociated with aADHD on a nominal significance level. A two-stage analysis resulted in one 
SNP being associated with aADHD even after correction for multiple testing. Therefore, 
the replication of the association findings for aADHD can be deemed as successful. The 
protective haplotype found in the aADHD sample from Germany did neither emerge in 
one of the other aADHD samples nor in one of the family samples for ADHD. Thus, this 
finding with a p value of 0.0394 has maybe to be considered as a false positive one. The 
single marker association findings in the cADHD sample from Würzburg mainly show no 
overlap with those in the aADHD samples. The only marker which showed an association 
with both adult and childhood ADHD is rs4077621, located in intron 5 of the CDH13 gene. 
The single marker findings in the replication sample for cADHD from Homburg were also 
different from those in the aADHD sample as well as from those in the initial cADHD sam-
ple. However, genetic variations which are in high linkage disequilibrium to the SNPs that 
showed an association with ADHD in this study may represent the risk alleles for the dis-
ease. As with every association study, the possibility of false positive findings has to be 
considered. With 86 SNPs genotyped in the initial samples and 58 in the respective repli-
cation samples and a significance threshold of 0.05, 3 – 4 false positive findings (5% of the 
tested SNPs) per association analysis are to be expected. Nevertheless, the fact that ten 
SNPs were found to be associated with aADHD and six to be associated with cADHD in the 
first studies, taken together with the association of up to 20 SNPs (20 SNPs in the German 
aADHD sample, 12 in the Dutch aADHD sample, 15 SNPs in the cADHD sample from 
Würzburg and 8 in the cADHD sample from Homburg) with co-morbidities within the 
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ADHD samples, strongly indicates an involvement of CDH13 in ADHD genetics. The results 
gained in the association studies of CDH13 with PD further substantiate the assumption 
that this gene also plays a role in psychiatric disorders related to ADHD. The result of four 
SNPs associated with PD with one of them being significantly associated with cluster B PD 
after Bonferroni correction can be considered as a robust association finding. Three of 
those SNPs associated with PD were also found to be associated with aADHD. However, a 
replication in an independent sample is desirable. Notably, the significant SNPs found in 
the PD sample are also clustered at the 3´region of the CDH13 gene the same way as most 
significant SNPs associated with aADHD are (Figure 3.4). Two of those clustering SNPs 
showed exceptionally high associations with both aADHD and PD (rs11642219: aADHD p = 
0.0003, PD p = 0.00001 significant after correction; rs692612: aADHD p = 0.001, PD p = 
0.0013). The risk allele of rs692612 produces a predicted homeodomain transcription 
factor binding site while the risk allele for the other SNP leads to the generation of an E2F 
binding site and the loss of a binding site for the mammalian transcriptional repressor 
RBP-Jkappa/CBF1. The nuclear factor E2F is known to be involved in cell cycle regulation 
and the human MYC promoter is a target of this transcription factor (Thalmeier 1989). 
Although these polymorphisms are located at the 3´part of the CDH13 gene they might 
alter the expression of the gene. According to the Ensembl genome browser one isoform 
of CDH13 has its transcriptional start site near the 3´end of the gene and may therefore 
be influenced by variations in this region. Another possibility is that those regulatory ele-
ments have an effect on the expression of other genes located downstream the CDH13 
gene. In this case CDH13 itself would not be the candidate gene for ADHD but would con-
tain critical DNA features for the regulation of the de facto candidate gene situated near-
by. Possible alternative candidates are the NECAB2 gene which is also highly expressed in 
the brain and which is coding for the Neuronal calcium-binding protein 2 (also called Syn-
aptotagmin-interacting protein 2) or the HSFBP1 gene that is coding for the heat shock 
factor binding protein 1. As a consequence, despite all the evidences that point to CDH13 
as a potent candidate gene for ADHD there is still clear need to further investigate the 
Chromosome 16q24 locus and the genes it harbors as well as the translational regulation 
of the CDH13 gene and its adjacent genes. 
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4.3. DIRAS2 
Based on the findings of four independent hypothesis free approaches- two linkage scans 
on childhood ADHD, a GWAS of adult ADHD and a GWAS of PD- DIRAS2 was considered as 
a candidate gene for ADHD and a fine-mapping of this gene located on chromosome 9q22 
was performed. Tagging SNPs situated in the promoter region, the coding sequence and 
the 3´UTR of the gene were analyzed in seven independent patient samples. Two of the 
four SNPs which were found to be associated with aADHD in the initial sample from Ger-
many are located in the 3´UTR (rs7854469 and rs16906711) and two are located in the 
upstream regulatory region of the DIRAS2 gene (rs1331503 and rs1412005). The initial 
association findings in aADHD were successfully replicated in the independent sample of 
the IMpACT collaboration using a meta-analytic approach. The risk haplotype identified 
for aADHD spans the promoter region of the DIRAS2 gene and the associated SNP which 
was found in the meta-analysis (rs1412005) is contributing to this haplotype. The only 
marker (rs7848810) that showed an association with childhood ADHD is also located with-
in this regulatory region and component of this haplotype as well. Searching for transcrip-
tion factor binding motifs revealed that the sequence carrying the major allele of 
rs7848810 contains predicted response elements for PBX1 and for the PBX-HOXA9 dimer. 
It is known that PBX1 plays a role in the developmental regulation of neuropeptide Y ex-
pression (Mayer 2003), whereas PBX-HOX dimers are involved in vertebrate development 
in general (Moens and Selleri, 2006). Risk allele carriers may therefore have an impaired 
developmental expression of DIRAS2. Due to the fact that all markers and the haplotype 
block that showed an association with ADHD are located in potential control regions of 
gene expression, it can be hypothesized that changes in the expressional control of 
DIRAS2 underlie the ADHD association. The role of the risk alleles identified in this work in 
respect to the regulation of gene expression needs to be further investigated using tools 
like luciferase promoter assays. 
 
The association study results gained from the genotyping data of the bipolar and PD sam-
ples show that association of DIRAS2 with ADHD is not specific for this disease, but also 
occurs for other disorders. Considering the co-morbidity of these disorders with aADHD, 
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those findings may provide a genetic basis for these clinical observations. It has to be re-
flected which neurobiological phenotype is modulated by DIRAS2. Indications might be 
obtained from personality genetics, as nine DIRAS2 SNPs were associated with personality 
domains in aADHD or PD patients. For example, aADHD patients carrying the rs1412005 T 
allele show on average 3.6 point lower Conscientiousness and 1.4 point higher Harm 
Avoidance scores than non-carriers (Table 3.9). Therefore, DIRAS2 seems to predispose to 
a characteristic personality profile observed in ADHD, which might best be characterized 
by reduced Conscientiousness and increased Harm Avoidance. However, it has to be not-
ed that associations varied between samples so that these data can only be considered 
preliminary and there is clear need of further replication. 
 
To get more knowledge about candidate genes which have been identified in association 
studies, expression studies as well as functional studies are needed. As almost nothing is 
known about the DIRAS2 gene, its expression in the brain was further investigated in this 
work. The expression pattern of Diras2 in the mouse brain provides further support to the 
assumption that this gene is involved in the pathophysiology of ADHD. 
Volume anomalies of subcortical structures, specifically of the basal ganglia, hippocampus 
and amygdala in patients suffering from ADHD have been reported in structural neuroim-
aging studies (Shaw and Rabin, 2009). Therefore, the expression of a candidate gene for 
this disorder in regions like the amygdala and hippocampus like it was observed for Diras2 
expression is not surprising. 
 
The hippocampus is mainly known for its function in memory processing. It belongs to the 
limbic system of which the amygdala is also a part. The entorhinal cortex (EC) is consid-
ered a part of the hippocampal region because of its anatomical connections. Within the 
hippocampus, the flow of information from the EC is largely unidirectional. First , the per-
forant fiber pathway projects to the granule cells of the dentate gyrus, then the mossy 
fibers of those cells project to the pyramidal cells in the CA3 layer which are connected to 
the pyramidal cells of the CA1 layer through the Schaffer collateral pathway. The infor-
mation is then transmitted to the subiculum and there it is forwarded out of the hippo-
campus to the EC. Beyond the output to the EC, additional output pathways go to other 
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cortical areas including the prefrontal cortex. There is also output from the hippocampus 
to the lateral septal area. It is hypothized that that hippocampal dysfunction could pro-
duce an alteration of dopamine release in the basal ganglia, especially in the nucleus ac-
cumbens (NAcc), thereby indirectly affecting the integration of information in the pre-
frontal cortex. Adaptive modifications in dopaminergic system balance are important for 
enabling the NAcc to shift between limbic and cortical drives like the amygdala and the 
hippocampus and the PFC (Goto and Grace, 2008). 
 
Diras2 expression in the amygdala was limited to the basolateral nucleus. The basolateral 
amygdala (BLA) projects heavily to the nucleus accumbens and also reciprocally to the 
hippocampus. Bidirectional projections connect the medial prefrontal cortex and basolat-
eral amygdala. This circuit has been suggested to play a role in fear extinction. Abnormali-
ties in the projections from the medial prefrontal cortex to the basolateral amygdala have 
been observed in schizophrenics. A recent study in rats revealed that the perinatal expo-
sure to bisphenol-A (BPA), which causes GABAergic disinhibition and dopaminergic en-
hancement, leads to an abnormal cortical-BLA synaptic transmission and plasticity. Those 
changes might be responsible for the observed hyperactivity and attention-deficit in BPA-
rats (Zhou R. , 2011). 
 
In a MRI study which compared children with ADHD to healthy controls an enlargement 
of the hippocampus and reduced size of the basolateral complex of the amygdala was 
found. Correlations with prefrontal measures suggested abnormal connectivity between 
the amygdala and prefrontal cortex in the ADHD group. Those findings again suggest an 
involvement of the limbic system in the pathophysiology of ADHD (Plessen 2006). 
 
The mitral cells of the olfactory bulb receive input from the olfactory receptor neurons. 
They convey information through the anterior olfactory nucleus to several brain regions 
including the piriform cortex, the amygdala and the entorhinal cortex. Romanos et al. 
reported an increase in odor sensitivity in children suffering from ADHD (Romanos 
2008b). The expression of Diras2 in the mitral cells, the anterior olfactory nucleus and the 
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piriform cortex might indicate an involvement of this gene in the observed changes in 
olfactory perception in ADHD.  
 
Since the cerebral cortex is much smaller and less complex in rodents than it is in humans, 
it is difficult to compare particular cortical areas in these two species. Especially the pre-
frontal cortex - one of the brain regions strongly linked to ADHD - was considered to be 
unique to primates. Nonetheless, today there are several studies on rats indicating the 
existence of cortical structures with homologies to the prefrontal cortex in primates 
(Uylings 2003) (Seamans 2008). Less is known about the prefrontal cortical areas of mice 
which have been characterized cytoarchitectonically and chemoarchitectonically quite 
recently (Van De Werd 2010). In one study it was found that mice exhibit affective and 
attentional sets like rats and primates and that those functions are disrupted by medial 
and orbital prefrontal cortical lesions (Bissonette 2008) indicating a possible role of the 
mouse prefrontal cortical areas similar to that of the prefrontal cortex in primates. Hence, 
the expression of a candidate gene for ADHD in the orbital cortex of mouse brains is in 
line with the involvement of the prefrontal cortex in the pathophysiology of ADHD in hu-
mans. 
 
The lateral septum (LS) is thought to be of central importance for the control of mood and 
motivation. There is evidence that this brain region is involved in several psychiatric dis-
orders like schizophrenia, depression or anxiety disorders due to its role in affective regu-
lation. The LS receives glutamatergic input from the hippocampus and is composed of 
GABAergic neurons projecting to various hypothalamic cell groups and midbrain regions. 
Moreover, the LS receives input from the amygdala, the frontal cortex, the bed nucleus of 
the stria terminalis and the entorhinal cortex, which are structures known for their regu-
latory impact on emotional states (Sheehan 2004). Therefore, the lateral septum may also 
play a part in the emotional dysregulation in ADHD and co-morbid disorders. 
 
As the dopaminergic system is assumed to be highly involved in the pathophysiology of 
ADHD, the substantia nigra as a core structure of this system may be of interest for this 
disease as well. The dopaminergic terminations in the striatum originate mainly from the 
Discussion 
58 
 
substantia nigra. Thus, the spot-wise in situ hybridization staining in the striatum could 
constitute neuronal endings deriving from the substantia nigra which was found to con-
tain Diras2 mRNA. An enlargement of the echogenic substantia nigra area could be ob-
served in children with ADHD compared to controls in two independent studies (Romanos 
2010) (Krauel 2010). In one study a correlation with symptoms of inattention, hyperactivi-
ty, and impulsivity was found. The results of those studies support the idea that the ni-
grostriatal system is altered in ADHD. 
 
In addition to the dopaminergic system, the noradrenergic system is considered to be 
involved in ADHD. A majority of the noradrenergic neurons of the brain are concentrated 
in the locus coeruleus, a brain stem nucleus. This nucleus is the primary source of nora-
drenergic innervation of the forebrain and the sole source of norepinephrine to the hip-
pocampus and the neocortex. Norepinephrin modulates the collection and processing of 
noticeable sensory information through its action on sensory, memory, attentional and 
motor processes. It is assumed that dysfunction of the locus coeruleus noradrenergic sys-
tem may lead to deficits in cognitive and affective processes that are associated with dis-
orders like ADHD. There is evidence that the action of psychostimulant drugs used for the 
treatment of ADHD involves the locus coeruleus norepinephrine system (Berridge and 
Waterhouse, 2003). A study on the effect of methylphenidate (MPH) on the locus co-
eruleus suggested that the behavioral-calming and cognition-enhancing actions of low-
dose MPH involve moderate actions on locus coeruleus discharge combined with altera-
tions in catecholamine neurotransmission within the prefrontal cortex (Devilbiss and 
Berridge, 2006). As the locus coeruleus is innervated by dopamingergic fibers from the 
ventral tegmental area and therefore is connected to the dopaminergic system, it is not 
clear if the detection of Diras2 mRNA in this area indicates the expression of this gene in 
noradrenergic neurons or in dopaminergic afferences. 
 
The parafascicular thalamic nucleus (PF) in which Diras2 expression was also observed is a 
part of the centromedian-PF complex in the caudal region of the intralaminar thalamus. 
The intralaminar thalamic nuclei seem to be important for attention and action selection 
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(Brown 2010). Therefore, the expression of Diras2 within this nucleus supports the as-
sumption that it is a potential candidate gene for ADHD. 
 
All of the brain regions in which Diras2 expression could be detected have been reported 
to be involved in the pathomechanisms of ADHD and/or to be altered in the disease. The 
observed expression pattern matches the idea of DIRAS2 as a candidate gene for ADHD. 
The expression levels of DIRAS2 in the human brain determined by qPCR fit the pattern 
found in the mouse brain. The highest expression levels were found in the hippocampus, 
the cerebral cortex and the cerebellum. RNA isolated from the human amygdala was not 
available. Therefore, no statement about DIRAS2 expression in this region in the human 
brain can be made. To review the expectation that the DIRAS2 expression pattern is the 
same or similar in the human and in the murine brain, in situ hybridization on human 
brain tissue would be necessary. 
 
To determine if Diras2 is expressed in components of the dopaminergic system and in 
GABAergic interneurons exclusively or if it is expressed for example in noradrenergic and 
serotonergic neurons as well, further studies are needed, especially those working with 
double labeling on brain tissues and primary cells. The results of the immunocytochemical 
double staining of mouse hippocampal primary cells revealed a presence of Di-ras2 in 
GABAergic and dopaminergic neurons but not in glia cells. Expression of Diras2 in sero-
tonergic cells is to be expected, as a study investigating the distinct transcriptomes of 
rostral and caudal embryonic serotonergic neurons found a 13-fold increase of Diras2 in 
caudal serotonergic cells (Wylie 2010). Also, in situ hybridizations and immunohistochem-
ical staining on sagittal and horizontal brain sections will be useful to recognize the brain 
regions in which Di-ras2 occurs. 
 
The fact that no clear Di-ras2 expression was found in any of the investigated human cell 
lines, especially in cancer cell lines, may be due to a down regulation of the expression of 
this Ras kinase in tumor cells like it is the case for the homologue kinase ARHI. Further 
examination of the function of Di-ras2 in neuroblastoma cells, such as over expression 
studies, may give insights into its cellular function. 
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The investigation of Diras2 expression during mouse brain development by qRT PCR re-
vealed a significant increase of expression levels during the early developmental stages. 
The expression reaches its summit in the late postnatal phase which was defined as post-
natal day 9 – 15. This expression maximum stays stable until adulthood. Those results 
could be interpreted in a way that Diras2 being important in the brain at later develop-
mental stages. However, developmental time lines between different species cannot be 
matched precisely. Clancy et al. developed a model for translating time across different 
mammalian species during neural development (Clancy 2001). In this model, postnatal 
days 8.8 to 11.2 in the mouse brain are comparable to 138 to 201 days after conception in 
humans. Therefore, a similar time course in Diras2 expression in the human brain could 
mean that its expression reaches its maximum during prenatal brain development. To 
elucidate the possible role of Diras2 during human brain development, further studies to 
clarify its function on a cellular level are needed and have to be carried out with human 
tissue.  
4.4. Conclusion and outlook 
In conclusion the results of this work provide further support to the existence of a strong 
genetic component in the pathophysiology of ADHD and related disorders.  
 
However, several points have to be considered in the interpretation of the data presented 
in this work. Given the genetic effect sizes (odds ratio) estimated in the aADHD discovery 
sample (1020 German individuals), the replication sample (2416 individuals from IMpACT) 
had sufficient power to detect the effects of the rs1412005 T allele and the ACGCTT hap-
lotype of the Diras2 gene and the effects of the risk alleles of the markers rs4591132, 
rs2228685, rs11642219 and rs153653 in the CDH13 gene. Despite this fact, there still is a 
chance of false-positive findings. This is relevant as most associations on the single mark-
er level would not withstand correction for multiple testing, which becomes an even 
more prominent issue when examining multi-axial dimensional data such as personality 
traits. However, in case of a successful replication in several independent populations as 
achieved for the association studies concerning the DIRAS2 and the CDH13 gene, and in 
conjunction with previous evidence from linkage studies and GWAS, it might be assumed 
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that there are true associations between those genes and ADHD. It can be speculated that 
genetic variations within the investigated candidate genes, in linkage disequilibrium with 
the genotyped SNPs, are the risk alleles, a hypothesis which will have to be tested in fur-
ther studies using re-sequencing approaches followed by functional studies. Finally, as 
strong positive findings were not obtained from all samples, small individual sample size, 
background, epistatic or founder effects or even gene-environment interaction may also 
play a role in explaining the fact that genetic variants contribute to ADHD and related 
phenotypes in some, but not all populations.  
 
The results of the expression studies of Diras2 promote this gene as an interesting candi-
date gene for ADHD. However, its function and the pathways via which it acts are still 
unknown. One can speculate that Di-ras2, like other Ras kinases, may be involved in cell 
growth and cell morphology and therefore may also be involved in the volume changes of 
several brain regions observed in ADHD patients. To investigate if the identified risk al-
leles and the risk haplotype situated in the promoter region of the Diras2 gene alter the 
expression levels of this gene, sequencing as well as promoter studies are needed. Also, a 
closer look at the promoter methylation might give new insights into the expressional 
regulation of this gene, as the expression of the homologous ARHI gene is known to be 
down regulated via methylation of the promoter region. 
 
Taken together, the investigated genes are promising candidates and need to be further 
examined to acquire more knowledge about the neurobiological basis of this common 
disease. This knowledge is essential for understanding the molecular mechanisms under-
lying the emergence of this disorder and for the development of new treatment strate-
gies. 
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